WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5:

A61K 31/435, C07D 221/02

(11) International Publication Number:

WO 93/23041

A1

(43) International Publication Date: 25 November 1993 (25.11.93)

(21) International Application Number:

PCT/US93/04771

(22) International Filing Date:

19 May 1993 (19.05.93)

(30) Priority data:

886,022

20 May 1992 (20.05.92)

US

(60) Parent Application or Grant

(63) Related by Continuation US

886,022 (CIP)

Filed on

20 May 1992 (20.05.92)

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): WITZEL, Bruce, E. [US/US]; 115 Scotch Plains Avenue S., Westfield, NJ 07090 (US). RASMUSSON, Gary, H. [US/US]; 155 Park Place, Watchung, NJ 07060 (US). TOLMAN, Richard, L. [US/US]; 29 Upper Warren Way, Warren, NJ 07059 (US). YANG, Shu, Shu [US/US]; 324 Eileen Way, Bridgwater, NJ 08807 (US).

(74) Agent: QUAGLIATO, Carol, S.; 126 East Lincoln Avenue, Rahway, NJ 07065 (US).

(81) Designated States: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: ESTER DERIVATIVES OF 4-AZA-STEROIDS

(57) Abstract

Compounds of formula (I), wherein X is sulfur or oxygen are inhibitors of the 5a-reductase enzyme and isozymes thereof. The compounds are useful for the treatment of hyperandrogenic disease conditions and diseases of the skin and scalp.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	- GA	Gabon	MW	Malawi
BB	Barbados .	GB	United Kingdom	NĽ	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece ·	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PŁ	Poland
BJ	Benin ·	IE	Ireland	PT	Portuga!
BR	Brazil	IT	lialy	. RO	Romania
ĊA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic	· SD	Sudan
CG	Cango		of Korea	SE	Sweden
CH	Switzerland	. KR	Republic of Korea	SK	Slovak Republic
CI	Côte d'Ivoire	KZ	Kazakhstan	SN	Senegal
CM	Cameroon	· ii	Liechtenstein	· SU	Soviet Union
CS	Czerhoslovakia	LK	Sri fanka	TD	Chad
cz	Czech Republic	0.1	Luxembourg	TC	Tago
DE	Germany	MC	Munaco	UA	Ukraine
DK	Denmark	MG	Madagascar	US	United States of America
ES	Spain	M1.	Mali	VN -	Viet Nam
FI	Finland	MN	Mongelia		•.

10 TITLE OF THE INVENTION
ESTER DERIVATIVES OF 4-AZA-STEROIDS

BACKGROUND OF THE INVENTION

The present invention is directed to new 17-position ester and thioester derivatives of 4-azaandrostan-3-ones and related compounds and the use of such compounds as 5α -reductase inhibitors.

The art reveals that certain undesirable physiological manifestations, such as acne vulgaris, seborrhea, female hirsutism, male pattern baldness and benign prostatic hypertrophy, are the result of hyperandrogenic stimulation caused by an excessive accumulation of testosterone or similar androgenic hormones in the metabolic system. Early attempts to provide a chemotherapeutic agent to counter the undesirable results of hyperandrogenicity resulted in the discovery of several steroidal antiandrogens having undesirable hormonal activities of their own.

20

The estrogens, for example, not only counteract the effect of the androgens but have a feminizing effect as well. Non-steroidal antiandrogens have also been developed, for example, 4'-nitro-3'-trifluoromethyl-isobutyranilide. See Neri, et al., Endo., Vol. 91, No. 2 (1972). However, these products, though devoid of hormonal effects, are peripherally active, competing with the natural androgens for receptor sites, and hence have a tendency to feminize a male host or the male fetus of a female host.

It is now known in the art that the principal mediator of androgenic activity in some target organs is 5α-dihydrotestosterone, and that it is formed locally in the target organ by the action of testosterone-5α-reductase. It is also known that inhibitors of testosterone-5α-reductase will serve to prevent or lessen symptoms of hyperandrogenic stimulation.

A number of 4-aza steroid compounds are
known in the art as 5α-reductase inhibitors. For example, See U.S. Patent Nos. 2,227,876, 3,239,417, 3,264,301 and 3,285,918; French Patent No. 1,465,544; Doorenbos and Solomons, J. Pharm. Sci. 62, 4, pp. 638-640 (1973); Doorenbos and Brown, J. Pharm. Sci., 25 60, 8, pp. 1234-1235 (1971); and Doorenbos and Kim, J. Pharm. Sci. 63, 4, pp. 620-622 (1974).

In addition, U.S. Patent Nos. 4,377,584, 4,220,775, 4,859,681, 4,760,071 and the articles

J. Med. Chem. 27, p. 1690-1701 (1984) and J. Med.

30 Chem. 29, 2998-2315 (1986) of Rasmusson, et al., U.S.

Patent 4,845,104 to Carlin, et al., and U.S. Patent 4,732,897 to Cainelli, et al. describe 4-aza-17B-substituted-5 α -androstan-3-ones which are said to be useful in the treatment of DHT-related hyper-androgenic conditions.

However, despite the suggestion in the prior art that hyperandrogenic diseases are the result of a single 5α-reductase, there are reports regarding the presence of other 5α-reductase

10 isozymes in both rats and humans. For example, in human prostate, Bruchovsky, et al. (See J. Clin. Endocrinol. Metab. 67, 806-816, 1988) and Hudson (see J. Steroid Biochem. 26, p 349-353, 1987) found different 5α-reductase activities in the stromal and epithelial fractions. Additionally, Moore and Wilson described two distinct human reductases with peaks of activities at either pH 5.5 or pH 7-9. (See J. Biol. Chem. 251, 19, p. 5895-5900, 1976.)

Recently, Andersson and Russell isolated
20 a cDNA which encodes a rat liver 5α-reductase (see
J. Biol. Chem. 264 pp. 16249-55 (1989). They found
a single mRNA which encodes both the liver and
prostatic reductases of rats. The sequence of this
rat gene was later used to select a human prostatic
25 cDNA encoding a 5α-reductase termed "5α-reductase 1".
(See Proc. Nat'l. Acad. Sci. 87, p. 3640-3644, 1990.)

More recently, a second, human prostatic reductase (5α-reductase 2) has been cloned with properties identified with the more abundant form found in crude human prostatic extracts. (See Nature, 354, p. 159-161, 1991.)

_ 4 -

Further, "Syndromes of Androgen Resistance" - The Biology of Reproduction, Vol. 46, p. 168-173 (1992) by Jean O. Wilson indicates that the 5α -reductase 1 enzyme may be associated with hair follicles.

Thus, the art supports the existence of at least two genes for 5α -reductase and two distinct isozymes of 5α -reductase in humans. Both forms are present in prostatic tissue in which, 5α -reductase 2, is the more abundant, and the other isozyme,

10 5α -reductase 1, is believed to be more abundant in scalp tissue.

In the treatment of hyperandrogenic disease conditions, e.g. benign prostatic hyperplasia (BPH), it would be desirable to have one drug entity which is active against both enzymes 1 and 2 in the prostate to substantially inhibit dihydrotestosterone (DHT) production. Alternatively, it would be desirable to have a drug entity which is highly selective for inhibiting the scalp associated enzyme 5α-reductase 1, for use in treating diseases of the skin and scalp, e.g. acne and alopecia. The drug could also be used in combination with PROSCAR® (finasteride) which is highly selective for the prostatic enzyme 5α-reductase 2 for combination therapy in the treatment of BPH.

25

5.

SUMMARY OF THE INVENTION

The present invention discloses novel
17-position ester and thioester derivatives of
4-azaandrostan-3-ones and related compounds which are

useful for inhibiting the steroid 5α -reductase enzymes 1 and 2. The compounds are particularly effective in selectively inhibiting the 5α -reductase 1 associated with the scalp, and dually inhibiting both isozymes 1 and 2 in the oral, parenteral or topical treatment of benign prostatic hyperplasia, acne, female hirsutism, male pattern baldness, androgenic alopecia, prostatitis, and the prevention and treatment of prostatic carcinoma.

10 .

DETAILED DESCRIPTION

This invention is concerned with compounds of formula I, and combinations thereof for the selective inhibition of 5α -reductase 1 and the combined inhibition of 5α -reductase 1 and 2. Compounds of formula I are defined as follows:

20
$$(CHR^{1})_{n}-X-C-R^{4}$$

$$\downarrow a$$

$$\downarrow b$$

$$\downarrow a$$

$$\downarrow b$$

$$\downarrow a$$

$$\downarrow b$$

$$\downarrow a$$

$$\downarrow B$$

wherein a and b are both single bonds and R² is hydrogen, or

a is a double bond, b is a single bond and R² is hydrogen, or

 $\underline{\mathbf{a}}$ is a single bond, $\underline{\mathbf{b}}$ is a double bond and \mathbb{R}^2 is absent;

R¹ is -H, ary1, or -C₁₋₃alkyl unsubstituted or substituted with aryl and can be the same or different at each occurrence when n is greater than 1;

R³ is -H, methyl, ethyl, -OH, -NH₂ or -SCH₃; n is an integer selected from zero through 10;

10 X is -0- or -S-; and R^4 is 1) -C₁₋₂₀ alkyl, unsubstituted

or substituted with one or more of:

- a) -OH,
- b) halo,
- c) $-C_{1-8}$ alkoxy,
- d) $-C_{1-6}$ alkenyl,
- e) $-CONR^5R^5$, wherein R^5 is independently
 - i) -H,
 - ii) -C₁₋₈ alkyl unsubstituted or substituted with one or more of R⁷, aryl or heterocycle, the aryl being unsubstituted or substituted with one or more of R⁷ or R⁹,
 - iii) aryl unsubstituted or substituted with one or more of R⁷ or R⁹, or
 - iv) heterocycle, unsubstituted or substituted with one or more of R⁷ or R⁹,
- f) -COOR6, wherein R6 is
 - i) -H,

15

20

25

		ii) -C ₁₋₈ alkyl unsubstituted or
		substituted with one or more of
		R^7 or aryl, the aryl being
		unsubstituted or substituted
5		with one or more of R ⁷ or R ⁹ ,
		or
		iii) aryl, unsubstituted or
		substituted with one or more of
		R^7 or R^9 ,
10		g) $-S(0)_p-R^5$, wherein p is zero, 1 or 2;
		$h) -N(R^{5})_{2},$
		i) ary1, unsubstituted or substituted
		with one or more of aryl, R ⁷ or R ⁹ ,
		j) heterocycle, unsubstituted or
15		substituted with one or more of R7
		or R ⁹ ,
		k) -C ₃₋₁₀ cycloalky1, such as
		cyclohexyl, norbornyl, or
		adamantyl, unsubstituted or
20		substituted with one or more of R7
	•	or R ⁹ , or
•		1) $-CONR^8-CO-NHR^8$, wherein R^8 is $-H$,
		-C ₁₋₈ alkyl, benzyl or cyclohexyl,
	2)	aryl, unsubstituted or substituted with
25		one or more of aryl, R^7 or R^9 ,
	3)	heterocycle or -C ₃₋₁₀ cycloalky1,
		either of which is unsubstituted or
		substituted with one or more of R ⁷ or
,		R ⁹ ,
30	4)	$-NR^5R^5$, or
	5)	-0R ⁵ ;

	R' is	1)	· - 0H,
		2)	$-C_{1-3}$ alkoxy,
	•	3)	-CN,
		4)	-coor ⁶
5		5)	-C ₁₋₈ alky1-C00R ⁶
			-NO ₂ , or
	•	7)	halo; and
	·	8)	amino, mono- C_1 - C_4 alkylamino, di- C_1 - C_4 -alkylamino;
10	•		•
	R ⁹ is	1)	-C ₁₋₈ alky1, unsubstituted or
			substituted with one or more of aryl or \mathbb{R}^7 ,
	•	2)	-CO-A, -C ₁₋₈ alky1-CO-A, -NHCO-A, or
15	٠ .	•	·-S(0) _p -A, wherein p is defined above and A is
		-	a) -H,
			b) -C ₁₋₈ alkyl, unsubstituted or
			substituted with one or more of
20			i) -R ⁷ , or
	•		ii) ary1, unsubstituted or
	•		substituted with one or more of \mathbb{R}^7 , or
			c) aryl, unsubstituted or
25		-	substituted with one or more of ${\tt R}^7$,
		3)	-NHCO-heterocycle,
		4)	$-N(R^{10})_2$ or $-CON(R^{10})_2$ wherein R^{10} is
			independently, heterocycle or -A,
_		5)	- Y
30		-	and Q is $-N(R^{10})_2$ or $-0R^{10}$;

10

with the provisos that:

when n is 1-10, <u>b</u> is a single bond, R^1 is -H at each occurrence, X is -0-, and R^4 is -C₁₋₆alkyl, R^4 is not substituted with an unsubstituted phenyl ring;

when n is 1-10, <u>b</u> is a single bond, R^1 is -H at each occurrence, and X is -0-, R^4 is not unsubstituted C_{5-10} cycloalkyl, unsubstituted phenyl, amino, $-C_{1-8}$ alkyl substituted amino, or $-C_{1-8}$ alkoxy;

when n is zero, X is -0-, a and b are both single bonds and R³ is -H, then R⁴ is not -CH₃; and when n is 1, R¹ is -CH₃, X is -0-, a and b are both single bonds, and R³ is -H, then R⁴ is not -CH₃;

or a pharmaceutically acceptable salt or ester thereof.

A first preferred embodiment of this invention is represented by compounds of formula II

20

25

wherein R^4 is $-C_{1-20}$ alky1, unsubstituted or substituted with one or more of

-OH, halo, -C₁₋₈alkoxy, -C₁₋₆alkenyl, -S(0)_p-R⁵, -N(R⁵)₂, aryl unsubstituted or substituted with one or more of aryl, R⁷or R⁹, heterocycle unsubstituted or substituted with one or more of R⁷ or R⁹, or -C₃₋₁₀ cycloalkyl unsubstituted or substituted with one or more of R⁷ or R⁹, and X, p, R⁵, R⁷, and R⁹ are all as defined in formula I.

A second preferred embodiment of this invention is represented by compounds of formula II wherein R^4 is $-C_{1-20}$ alkyl substituted with $-\text{CONR}^5R^5$, $-\text{COOR}^6$ or $-\text{CONR}^8\text{CONHR}^8$, and X, R^5 , R^6 , and R^8 are all as defined in formula T

A third preferred embodiment of this
invention is represented by compounds of formula II
wherein R⁴ is

aryl unsubstituted or substituted with one or more of aryl, ${\bf R}^7$ or ${\bf R}^9$;

heterocycle unsubstituted or substituted with one or more of R⁷ or R⁹;

 $-c_{3-10}$ cycloalkyl unsubstituted or substituted with one or more of R^7 or R^9 ;

 $-NR^5R^5$; or $-0R^5$:

and X, \mathbb{R}^5 , \mathbb{R}^7 , and \mathbb{R}^9 are all as defined in formula 30 I.

A fourth preferred embodiment of this invention is represented by compounds of formula III

wherein R⁴ is -C₁₋₂₀ alkyl, unsubstituted or substituted with one or more of

-OH, halo, -C₁₋₈alkoxy, -C₁₋₆alkenyl, -S(0)_p-R⁵,
-N(R⁵)₂, aryl unsubstituted or substituted with one or more of aryl, R⁷ or R⁹, heterocycle unsubstituted or substituted with one or more of R⁷ or R⁹, or -C₃₋₁₀ cycloalkyl unsubstituted or substituted with one or more of R⁷ or R⁹, and X, n, p, R¹, R⁵, R⁷, and R⁹ are all as defined in formula I:

A fifth preferred embodiment of this invention is represented by compounds of formula III wherein R^4 is $-C_{1-20}$ alkyl substituted with $-CONR^5R^5$, $-COOR^6$ or $-CONR^8CONHR^8$, and X, n, R^1 , R^5 , R^6 , and R^8 are all as defined in formula I.

A sixth preferred embodiment of this invention is represented by compounds of formula III wherein \mathbb{R}^4 is

aryl unsubstituted or substituted with one or more of aryl, \mathbb{R}^7 or \mathbb{R}^9 ;

heterocycle unsubstituted or substituted with one or more of R⁷ or R⁹;

 $-C_{3-10}$ cycloalkyl unsubstituted or substituted with one or more of R^7 or R^9 ;

10 $-NR^5R^5$; or $-OR^5$; and X, n, R^1 , R^5 , R^7 , and R^9 are all as defined in formula I.

Unless other wise specified, the 17-substituent is assumed to be in the beta configuration.

Novel compounds of the present invention include but are not limited to the following compounds:

25

15

20-(11-(ethylthio)undecanoyloxy)-4-methyl-5 α 4-azapregnan-3-one,

5

20-ethoxyacetyloxy-4-methyl- 5α -4-azapregnan-3-one,

15

20

25

17-(12-(isopropylthio)dodecanoyloxy)-4-methyl- $5\alpha-4$ -azaandrostan-3-one,

30

20-(12-(isopropylthio)-dodecanoyloxy)-5 α -4-azapregn-1-ene-3-one,

 $17 \hbox{-acetyloxymethyl-4-methyl-5} \alpha \hbox{-4-azaandrostan-3-one,}$

- $4-methyl-20-tridecanoyloxy-5\alpha-4-azapregnan-3-one$, 20-t-butylacetyloxy-4-methyl-5α-4-azapregnan-3-one. $4-methy1-20-trimethy1acety1oxy-5\alpha-4-azapregnan-3-one$. $4-methyl-20-(10-undecenoyloxy)-5\alpha-4-azapregnan-3-one,$ $20-(3.7-dimethyl-6-octenoyloxy)-4-methyl-5\alpha-aza-$ 5 pregnan-3-one, 20-(3-carboxypropionyloxy)-4-methyl-5α-4-azapregnan-20-(11-(carbomethoxy)undecanoyloxy)-4-methy1-5 α -4azapregnan-3-one, 10 $20-(3-(carbobenzyloxy)propionyloxy)-4-methyl-5\alpha-4$ azapregnan-3-one, 20-(1-adamantylacetyloxy)-4-methyl-5α-4-azapregnan-3-one $4-methyl-20-(2-norbornylacetyloxy)-5\alpha-4-azapregnan-$ 15 3-one. 20-(3,4-dimethoxyphenyl)acetyloxy-4-methyl- 5α -4-azapregnan-3-one,
- 20-(4-isopropylphenyl)acetyloxy-4-methyl-5 α -4-aza
- 20 pregnan-3-one
 - 20-(isopropylthio)acetyloxy-4-methyl-5 α -4-aza-pregnan-3-one,
 - 20-(9-(isopropylthio)nonanoyloxy)-4-methyl-5 α -4-aza-pregnan-3-one,
- 25 20-(12-(isopropylthio)dodecanoyloxy)-4-methyl-5 α -4-azapregnan-3-one,

- 20-(11-(ethylsulfinyl)undecanoyloxy)-4-methyl-5 α -4-azapregnan-3-one,
- 20-(12-(t-butylthio)dodecanoyloxy)-4-methyl-5α-4-azapregnan-3-one
- 5 4-methy1-20-(4-(thien-2-y1))butyroyloxy-5α-4-azapregnan-3-one,
 - 20-trimethylacetyloxy- 5α -4-azapregnan-3-one,
 - 20-(9-(isopropylthio)nonanoyloxy)-5 α -4-azapregnan-3-one.
- 20-(12-(isopropylthio)dodecanoyloxy)-5α-4-azapregnan-3-one,
 - 20-acetoxymethy1-4-methy1-5 α -4-azapregnan-3-one,
 - 4-methy1-20-(trimethylacetyloxy)methy1-5 α -4-aza-pregnan-3-one,
- 15 20-(12-(isopropylthio)dodecanoyloxy)methyl-4-methyl- 5α -4-azapregnan-3-one,
 - 4-methyl-17-trimethylacetyloxymethyl-5 α -4-azaandrostan-3-one,
 - 17-(2-ethylhexanoyloxy)methyl-4-methyl-5α-4azaandrostan-3-one,
 - 17-(12-(isopropylthio)dodecanoyloxy)methyl-4-methyl- 5α -4-azaandrostan-3-one,
 - 20-trimethylacetyloxy-5α-4-azapregn-1-ene-3-one,
 - 178-(benzylaminocarbonyloxy)-4-methyl-5 α -4-
- 25 azaandrostan-3-one,
 - 20-(t-butylaminocarbonyloxy)-4-methyl-5 α -4-azapregnan-3-one,

17-(t-butylaminocarbonyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one or

17-(methylaminocarbonyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one.

5

10

Novel compounds of the present invention further include, but are not limited to the following compounds:

- 17-(2-furylacetoxymethyl)-4-methyl-5 α -4-azaandrostan-3-one.
- 17-(4-isopropylphenylacetoxymethyl)-4-methyl-5 α -4-azaandrostan-3-one.
- 17-(cyclohexylacetoxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
- 15 17-(3-indolylacetoxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
 - 17-(4-methylcyclohexanecarbonyloxymethyl)-4-methyl- 5α -4-azaandrostan-3-one,
- $17-(4-(3-indoly1)-butyryloxymethyl)-4-methyl-5\alpha-4-$ 20 azaandrostan-3-one,
 - $17-(4-isobutylbenzoyloxymethyl)-4-methyl-5\alpha-4-$ azaandrostan-3-one,
 - 17-(acetoxyacetyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
- 25 17-(6-bromohexanoyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
 - 4-methy1-20-(4-nitrobenzoyloxymethy1)-5 α -4-azapregnan-3-one,
- 20-((3-acetamido)benzoyloxy)-4-methyl-5 α -4-30 azapregnan-3-one,

- 20-(3,4-dimethoxyphenylacetyloxymethyl)-4-methyl-5 α -4-azapregnan-3-one,
- 17-(4-ethoxybenzoyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
- 5 4-methyl-20-(palmitoyloxymethyl)-5 α -4-azapregnan-3-one.
 - 17-(iminodibenzyl-5-carbonyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
 - $4-methy1-20-(stearoyloxy)-5\alpha-4-azapregnan-3-one,$
- 10 17-(3,5-bis-(trifluoromethyl)benzoyloxymethyl)-4methyl-5α-4-azaandrostan-3-one,
 - 17-(3-cyanobenzoyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
 - 20-(heptafluorobutyryloxymethyl)-4-methyl-5 α -4-azapregnan-3-one,
 - 20-(4-benzoy1benzoy1oxymethy1)-4-methy1-5α-4azapregnan-3-one,
 - 17-(benztriazo1-5-carbonyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
- 20 20-(3,5-difluorobenzoyloxy)-4-methyl-5 α -4-azapregnan-3-one.
 - 17-(bis-(4-isopropyl)phenyl)acetyloxymethyl-4-methyl- 5α -4-azaandrostan-3-one,
 - 4-methy1-20-(salicylyloxymethy1)-5 α -4-azapregnan-3-one.
 - 17-((3-hydroxy-4,4,4-trichlorobutyryloxy)methyl)-4-methyl-5α-4-azaandrostan-3-one, or
 - 17-(cinnamoyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one.

25

Also included within the scope of this invention are pharmaceutically acceptable salts or esters, where a basic or acidic group is present in a compound of formula I, such as on the substituted alkyl, cycloalkyl, aryl or heterocyclic moiety. When an acidic substituent is present, i.e. -COOH, there can be formed the ammonium, sodium, potassium, calcium salt, and the like, for use as the dosage form.

Where a basic group is present, i.e. amino, acidic salts, i.e. hydrochloride, hydrobromide, acetate, pamoate, and the like, can be used as the dosage form.

Also, in the case of the -COOH group being present, pharmaceutically acceptable esters can be employed, e.g. acetate, maleate, pivaloyloxymethyl, and the like, and those esters known in the art for modifying solubility or hydrolysis characteristics for use as sustained release or prodrug formulations.

The compounds of the present invention, may have asymmetric centers and occur as racemates, racemic mixtures and as individual diastereomers, with all isomeric forms being included in the present invention.

When any variable (e.g., ary1, heterocycle, R¹, R², n, X, etc.) occurs more than one time in any constituent or in formula I, II or III its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

- 20 -

As used herein "alkyl" is intended to include both branched- and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms (Me is methyl, Et is ethyl, Pr is propyl, Bu is butyl); "alkoxy" represents an alkyl group of indicated number of carbon atoms attached through an oxygen bridge. "Cycloalkyl" is intended to include saturated mono-, bi- and tricyclic ring groups, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl (Cyh), cycloheptyl, norbornanyl and adamantyl. "Alkenyl" is intended to include hydrocarbon groups of either a straight or branched configuration with one or more carbon-carbon double bonds which may occur in any stable point along the chain, such as ethenyl, propenyl, butenyl, pentenyl, and the like. "Halo", as used herein, means fluoro, chloro, bromo and iodo.

1.0

20

30

As used herein, with exceptions as noted, "aryl" is intended to mean phenyl (Ph) or naphthyl.

The term heterocycle or heterocyclic, as used herein except where noted, represents a stable 5- to 7-membered monocyclic heterocyclic ring which is either saturated or unsaturated, and which consists of carbon atoms and from one to three heteroatoms selected from the group consisting of N, O and S, and wherein the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized, and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The heterocyclic ring may be attached

- 21 -

at any heteroatom or carbon atom which results in the creation of a stable structure. Examples of such heterocyclic elements include piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl,

- 5 2-oxopyrrolodinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl, pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolidinyl, isoxazolyl,
- isoxazolidinyl, morpholinyl, thiazolyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl, thiadiazoyl, benzopyranyl, benzothiazolyl, benzoxazolyl, furyl, tetrahydrofuryl,
- tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamorpholinyl sulfone, and oxadiazolyl. Morpholino is the same as morpholinyl. Preferred heterocycles are piperidinyl, 2-oxopyrrolodinyl, pyrrolyl,
- pyrazoly1, imidazoly1, pyridy1, pyraziny1,
 pyrimidiny1, pyridaziny1, oxazoly1, isoxazoly1,
 morpholiny1, thiazoly1, isothiazoly1, quinuclidiny1,
 indoly1, quinoliny1, isoquinoliny1, benzimidazoly1,
 thiadiazoy1, benzothiazoly1, benzoxazoly1, fury1,
- 25 tetrahydrofuryl, thienyl, and benzothienyl.

 "M.p." or "mp" is an abbreviation for melting point; "m.w." or "mw" is an abbreviation for molecular weight.

The compounds of the present invention are made by methods well known to those skilled in the The compounds of this invention are generally made from a steroid alcohol starting material,

5 . represented by formula (i)

15

20

25 -

30

10

wherein a and b are both single bonds and \mathbb{R}^2 is hydrogen, or

> a is a double bond, b is a single bond and R² is hydrogen, or

> a is a single bond, b is a double bond and R² is absent:

 R^1 is -H, aryl, or C_{1-3} alkyl unsubstituted or substituted with aryl and where n is greater than 1, R¹ can be the same or different; R³ is -H, methyl or ethyl; and n is an integer from zero through 10.

Methods of making starting alcohols of formula (i) are well known to those skilled in the art, and are described, for example, in the following publications: Rasmusson, G.H. et al., J. Med. Chem., 29, 2298-2315 (1986); Rasmusson, G.H. et al., J. Med. Chem., 27, 1690-1701 (1984).

Furthermore, the starting 4-azasteroid-20alcohols of Formula (i) may be made by several methods well known to those skilled in the art. example, 4-azasteroids containing a 17-carbonyl group 5 (e.g. carboxaldehyde) may be reacted with the appropriate organo-metallic reagent to yield the corresponding secondary alcohol, while reduction yields the primary alcohol. Also, an appropriate 17-ketone may be reduced (e.g. with sodium 10 borohydride) to the desired alcohol. The above mentioned ketones may be made by several methods well known in the art; one particularly useful method is that of A. Bhattacharya et al., Synthetic Communications 20(17), 2683-2690 (1990), in which an activated carbonyl compound is reacted with a suitable Grignard reagent to give the desired ketone. Other activated carbonyl compounds (e.g.

These alcohol functions may be constructed 20 both before and after the formation of the 4-aza moiety.

pyridine thioesters) may also be used.

One method of preparing compounds of formula

I is to condense the starting steroid alcohol with an

25 acid of formula (ii)

 R^4 -COOH (<u>ii</u>)

under conditions known to those skilled in the art,
30 e.g., in an appropriate solvent such as CH₂Cl₂, in
the presence of 4-(dimethylamino)-pyridine (DMAP) and
N,N'-dicyclohexylcarbodiimide (DCC).

Another method of preparing compounds of formula I is to combine the starting alcohol (i) with an acid chloride of formula (iii) or acid anhydride or mixed anhydride of formula (iv)

5 ·

25

30

 R^4 -COC1 (iii) (R^4 CO)₂O (iv)

under conditions known to those skilled in the art,
e.g. under dry conditions using an appropriate
solvent such as CH2Cl2 at e.g. reduced temperature,
such as about 0°C, in the presence of a base such as
pyridine.

Carbamate derivatives of formula I can be

prepared by reacting the starting alcohol (i) with an isocyanate compound, such as benzyl isocyanate or t-butylisocyanate for example, under conditions known to those skilled in the art, e.g., under dry conditions in an appropriate solvent such as benzene, in the presence of a base such as pyridine or 1,4-diazabicyclo[2.2.2]octane, or in the case of a hindered isocyanate such as t-butylisocyanate, 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), with

The thiol esters may be conveniently prepared from the corresponding alcohol via the literature procedure described in Tetrahedron Letters, 22 (1981) pp. 3119-3122, that is, the alcohol and a thiolacid are reacted together in the presence of the preformed adduct from triphenylphosphine and diisopropyl azodicarboxylate.

heating e.g. to 60°-70°C, or at room temperature.

Alternatively, the free thiol obtained from these thiolesters via standard saponification or reduction methods may then be acylated via standard procedures to obtain other thiolesters.

5

10

- 20

The variable "R⁴" used in the above synthetic method descriptions is defined in formula I, and is independently defined at each occurrence in formula (iv).

Accordingly, the present invention is particularly concerned with providing a method of treating the hyperandrogenic conditions of androgenic alopecia, acne vulgaris, seborrhea, benign prostatic hyperplasia, prostatitis, the prevention and/or treatment of prostatic carcinoma, by oral, parenteral or typical administration, of the novel compounds of the present invention.

The present invention is thus also concerned with providing suitable topical, oral and parenteral pharmaceutical formulations for use in the novel methods of treatment of the present invention.

The compositions containing the compounds of the present invention as the active ingredient for use in the treatment of e.g., benign prostatic hypertrophy, prostatitis, and prostatic carcinoma, and hyperandrogenic conditions can be administered in a wide variety of therapeutic dosage forms in conventional vehicles for systemic administration, as, for example, by oral administration in the form of tablets, capsules, solutions, or suspensions, of by injection. The daily dosage of the products may be varied over a wide range varying from 0.5 to 1,000

mg per adult human/per day. The compositions are preferably provided in the form of scored tablets containing 0.5, 1.0, 2.5, 5.0, 10.0, 15.0, 25.0, and 50.0 milligrams of the active ingredient for the symptomatic adjustment of the dosage to the patient 5 to be treated. An effective amount of the drug is ordinarily supplied at a dosage level of from about 0.002 mg. to about 50 mg./kg. of body weight per day. Preferably the range is from about 0.01 mg. to 7 mg./kgs. of body weight per day. These dosages are 10 well below the toxic dose of the product. Capsules containing the product of this invention can be prepared by mixing an active compound of the present invention with lactose and magnesium stearate, 15 calcium stearate, starch, talc, or other carriers, and placing the mixture in gelatin capsule. Tablets may be prepared by mixing the active ingredient with conventional tableting ingredients such as calciuim phosphate, lactose, corn starch or magnesium stearate. The liquid forms in suitably flavored 20 suspending or dispersing agents such as the synthetic and natural gums, for example, tragacanth, acacia, methylcellulose and the like. Other dispersing agents which may be employed include glycerin and the like. For parenteral administration, sterile 25 suspensions and solutions are desired. Isotonic preparations which generally contain suitable preservative are employed when intravenous administration is desired.

- 27 -

For the treatment of androgenic alopecia, acne vulgaris, seborrhea, female hirsutism, the compounds of the present invention are administered in a pharmaceutical composition comprising the active compound in combination with a pharmacologically acceptable carrier adapted for topical administration. Parenteral or oral administration are also applicable. These topical pharmaceutical compositions may be in the form of a cream, ointment, gel or aerosol formulation adapted for application to the skin. These topical pharmaceutical compositions containing the compounds of the present invention ordinarily include about 0.1% to 15%, preferably about 5%, of the active compound, in admixture with about 95% of vehicle.

The following examples are illustrative of representative embodiments of this invention and should not be construed to be limits on the scope or spirit of the instant invention.

The fast atom bombardment (FAB) and electron

impact (EI) mass spectral (MS) values are reported as
molecular ion peaks and are indicated as either M⁺,
M⁺¹, M⁻¹ or M⁺², being the molecular weight (mw), the
molecular weight plus one atomic mass unit, the
molecular weight minus one atomic mass unit, or the

molecular weight plus two atomic mass units.

The ¹H nuclear magnetic resonance (NMR) data was taken at 200 or 400 MHz and is tabulated for unique proton values of each compound at the end of the Examples.

5

10

- 28 -

Example 1

Preparation of 20-(11-(ethylthio)undecanoyloxy)-4-methyl-5α-4-azapregnan-3-one

To a stirred solution of 20-hydroxy-4-methyl5α-4-azapregnan-3-one (0.66 g, 2.0 mM), 11-ethylthioundecanoic acid (0.493 g, 2.0 mM), and 4-(dimethylamino)-pyridine (0.242 g, 2.0 mM) in methylene
chloride (25 mL) was added N,N'-dicyclohexylcarbodiimide (0.48 g, 2.3 mM) in methylene chloride (3 mL
plus 2x3 mL rinses) at room temperature. After
stirring overnight two times, the mixture was
filtered from the precipitated dicyclohexylurea and
concentrated, and the residue flash chromatographed
on silica gel using ethyl acetate as eluant to yield
the title compound as a thick oil. MS M+1 calculated
for C34H59NO3S, mw = 561.90; observed m/e 562.

Example 2

20

Preparation of 20-ethoxyacetyloxy-4-methyl-5α-4-azapregnan-3-one

Employing substantially the same procedure as described in Example 1, but substituting ethoxyacetic acid in place of the ethylthioundecanoic acid used therein, the title compound is obtained.

Example 3

Preparation of 17-(12-(isopropylthio)dodecanoyloxy)-4methy1-5α-4-azaandrostan-3-one

5

Employing substantially the same procedure as described in Example 1, but substituting 17-hydroxy-4-methyl-5α-4-azaandrostan-3-one and 12-(isopropylthio)dodecanoic acid for the 20-hydroxy-4-methyl-5α-4-azapregnan-3-one and 11-ethylthioundecanoic acid, respectively, used therein, the title compound was obtained. MS M⁺ calculated for C₃₄H₅₉NO₃S, mw = 561.92; observed m/e 561.

15

20

Example 4

Preparation of a) 20-(9-(isopropylthio)nonanoyloxy)-5α-4-azapregnan-3-one and b) 20-(12-(isopropylthio)dodecanoyloxy)-5α-4azapregn-1-ene-3-one

Employing substantially the same procedure as described in Example 1, but substituting the steroid alcohol and acid starting materials used therein with the following compounds, both of the title compounds were obtained:

Title compound a): 20-hydroxy-5 α -4-azapregnan-3-one and 9-(isopropylthio)nonanoic acid. MS M⁺ calculated for C₃₂H₅₅NO₃S, mw = 533.85; observed m/e 533;

Title compound b): $20-hydroxy-5\alpha-4-$ azapregn-1-ene-3-one and $12-(isopropylthio)dodecanoic acid. MS M⁺ calculated for <math>C_{35}H_{59}NO_3S$, mw = 573.92; observed m/e 573.

5

Example 5

Compounds of formula 3, below, were made employing substantially the same procedure as described in Example 1, but substituting the compounds of formula 1 and 2, below, in place of the 20-hydroxy-4-methyl-5\alpha-4-azapregnan-3-one and 11-ethylthioundecanoic acid respectively, used therein.

15

20

25

25

$$\begin{array}{c|c} & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & &$$

- 32 -

$$\frac{R^1}{m}$$
 $\frac{n}{m}$ $\frac{R^4}{m}$

a)
$$-CH_3$$
 zero $-(CH_2)_{11}CH_3$

b)
$$-CH_3$$
 zero $-CH_2CH(CH_3)CH_2CH_2CH=C(CH_3)_2$

c)
$$-CH_3$$
 zero $-CH_2-1$ -adamantyl

20 e)
$$-CH_3$$
 zero $-CH_2$ OCH3

f)
$$-CH_3$$
 zero

g)
$$-CH_3$$
 zero $-CH_2-S-CH(CH_3)_2$

h)
$$-CH_3$$
 zero $-(CH_2)_8-S-CH(CH_3)_2$

 $-(CH_2)_{11}-S-CH(CH_3)_2$

- 33 -

		R ¹	<u>n</u>	R ⁴ (CONT D)
5	i)	−CH₃	zero	$-(CH_2)_{11}-S-CH(CH_3)_2$
10	ίί	-CH₃	zero	-(CH ₂) ₁₁ -S-C(CH ₃) ₂
15	k)	−CH ₃	zero	-(CH ₂) ₃
20	1)	-CH₃	1	-(CH ₂) ₁₁ -S-CH(CH ₃) ₂
25	m)	-H	zero.	-CH(C ₂ H ₅)-CH ₂ CH ₂ CH ₂ CH ₃

zero

-H

n)

The compounds above have the following corresponding mass spectral data:

- a) MS M⁺ calculated for $C_{34}H_{59}NO_3$, mw=529.85; observed m/e 529;
 - b) MS M^+ calculated for $C_{31}H_{51}NO_3$, mw=485.75; observed m/e 485;
 - c) MS M⁺ calculated for $C_{33}H_{51}NO_3$, mw=509.78; observed m/e 509;
- - e) MS M⁺ calculated for $C_{31}H_{45}NO_5$; mw=511.71; observed m/e 511;
- f) MS M⁺ calculated for $C_{31}H_{45}NO_3$; mw=479.71; observed m/e 479;
 - g) MS M⁺ calculated for $C_{26}H_{43}NO_3S$; mw=449.69; observed m/e 449;
 - h) MS M⁺ calculated for $C_{33}H_{57}NO_3S$; mw=547.88; observed m/e 548;
- 20 i) MS M⁺ calculated for $C_{36}H_{63}NO_{3}S$; mw=589.94; observed m/e 589;
 - j) MS M^{+1} calculated for $C_{37}H_{65}NO_3S$; mw=604.00; observed m/e 605;
- k) MS M^{+1} calculated for $C_{29}H_{43}NO_3S$; mw=485.73; observed m/e 486;
 - 1) MS M^{-1} calculated for $C_{37}H_{65}NO_3S$; mw=604.00; observed m/e 603;
 - m) MS M⁺ calculated for $C_{28}H_{47}NO_3$; mw=445.69; observed m/e 445;
- 30 n) MS M⁺ calculated for $C_{35}H_{51}NO_3S$; mw=575.92; observed m/e 575.

- 35 -

Example 6

Preparation of 4-methy1-20-(10-undecenoyloxy)-5α-4-azapregnan-3-one

5.

To a solution of 20-hydroxy-4-methyl-5 α -4azapregnan-3-one (0.167 g, 0.5 mM) and pyridine (0.1 mL) in anhydrous methylene chloride (4.5 mL) at ice-bath temperatures was added 10-undecenoy1 chloride (0.13 mL, 0.6 mM) dropwise. After 10 10 minutes, the reaction mixture was allowed to warm to room temperature and stir overnight. After diluting further with methylene chloride the mixture was washed with dilute hydrochloric acid, water, and 15 brine, and dried (Na₂SO₄). The residue obtained from concentration of the filtered solution was flash chromatographed on silica gel using ethyl acetate as eluant to give the title compound as a glaze. MS M+ calculated for $C_{32}H_{53}NO_3$, mw = 499.78; observed m/e 20 499.

Example 7

Compounds of formula 6, below, were made
25 employing substantially the same procedure as
described in Example 6, but substituting the
compounds of formula 4 and 5, below, in place of the
20-hydroxy-4-methyl-5\alpha-4-azapregnan-3-one and
10-undecenoyl chloride, respectively, used therein.

10

15

20

25

a) $-CH_3$ zero $-CH_2C(CH_3)_3$ b) $-CH_3$ zero $-C(CH_3)_3$

•

c) $-CH_3$ zero $-(CH_2)_{10}COOCH_3$ d) $-CH_3$ zero $-CH_2CH_2COOCH_2-Ph$

e)

-CH₃ 1

-CH₃

30

f) $-CH_3$ 1 $-C(CH_3)_3$

g)

-H zero

-CH₃

h)

-H

zero

-C(CH₃)₃

The compounds above have the following corresponding mass spectral data:

- a) MS M⁺ calculated for $C_{27}H_{45}NO_3$, mw=431.67; observed m/e 431;
 - b) MS M^{+1} calculated for $C_{26}H_{43}NO_3$, mw=417.64; observed m/e 418;
 - c) MS M⁺ calculated for $C_{34}H_{57}NO_5$; mw=559.84; observed m/e 559;
- 10 d) MS M^{+2} calculated for $C_{32}H_{45}NO_5$; mw=523.72; observed m/e 525;
 - e) MS M⁺ calculated for $C_{24}H_{39}NO_3$; mw=389.59; observed m/e 389;
- f) MS M⁺ calculated for $C_{27}H_{45}NO_3$; mw=431.67; observed m/e 431;
 - g) MS M⁺ calculated for $C_{22}H_{35}NO_3$; mw=361.53; observed m/e 361;
 - h) MS M⁺ calculated for $C_{25}H_{41}NO_3$; mw=403.61; observed m/e 403.

20

Example 8

Preparation of 20-trimethylacetyloxy- 5α -4-azapregn-1-ene-3-one

Employing substantially the same procedure as described in Example 6, but substituting 20-hydroxy-5α-4-azapregn-1-ene-3-one and trimethylacetyl chloride for the 20-hydroxy-4-methyl-5α-4-azapregnan-3-one and 10-undecenoyl chloride, respectively, used therein, the title compound was obtained. MS M⁻¹ calculated for C₂₅H₃₉NO₃, mw =

402.53; observed m/e 401.

WO 93/23041 PCT/US93/04771

- 38 -

Example 9

Preparation of 20-(11-(ethylsulfinyl)undecanoyloxy)-4methyl-5α-4-azapregnan-3-one

To a stirred solution of 20-(11-(ethylthio)-5 undecanoyloxy)-4-methy1- 5α -4-azapregnan-3-one (0.056 g, 0.1 mM) in acetone (5 mL) at room temperature was added a solution of sodium periodate (0.033 mg, 0.154mM) in water (3 drops). After prolonged stirring with additional portions of the 10 periodate added (0.046 g total) over 3 days, the solvents were removed in vacuo, and the residue extracted with methylene chloride. The methylene chloride was removed in vacuo, and the resulting residue was flash chromatographed on silica gel (30% 15 acetone/methylene chloride eluant) to give the title compound as a glaze. MS M+ calculated for $C_{34}H_{59}NO_4S$, mw = 577.90; observed m/e 577.

20

25

Example 10

Preparation of 17ß-(benzylaminocarbonyloxy)-4-methyl-5α-4-azaandrostan-3-one

To a solution of 17B-hydroxy-4-methyl- 5α -4-azaandrostan-3-one (61 mg) in pyridine (0.60 ml) was added benzyl isocyanate (54 mg, 0.40 mmol). The mixture was stirred at 60-70°C under N_2 for 18 hr and pumped in vacuo to remove pyridine. The residue was purified using a silica gel plate (2000 μ) developed with ethyl acetate (Rf = 0.37, run in EtOAc) to give the title compound; m.p. is 216-217°C.

PCT/US93/04771

5

10

15

- 39 -

Example 11

Preparation of 20-(3-carboxypropionyloxy)-4-methyl-5α-4-azapregnan-3-one

 $20-(3-(Carbobenzyloxy)propionyloxy)-4-methyl-5\alpha-4-azapregnan-3-one (0.05 g, 0.095 mM) was reduced with hydrogen in ethyl acetate in the presence of 5% palladium on carbon, to obtain the title compound. MS M⁺¹ calculated for <math>C_{25}H_{39}NO_5$, mw=433.64; observed m/e 434.

Example 12

Preparation of 20-(acetylthiomethyl)-4-methyl-5α-4-azapregnan-3-one

By reacting 20-(hydroxymethy1)-4-methy1-5 α -4-azapregnan-3-one with thiolacetic acid as per the procedure of <u>Tetrahedron Letters 22</u> (1981) pp. 3119-3122, the title compound is obtained.

20

Example 13

Preparation of 17-(t-butylaminocarbonyloxymethyl)-4-methyl-5\alpha-4-azaandrostan-3-one

25

30

To a stirred solution of 17-(hydroxymethy1)-4-methy1-5α-4-azaandrostan-3-one (0.048 g, 0.15 mM) in dried benzene (5 mL) was added at room temperature t-butylisocyanate (0.03 mL, 0.23mM) followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) (0.023 mL, 0.15 mM). After stirring for two days, the volatiles WO 93/23041 PCT/US93/04771

- 40 -

were removed in vacuo and the residue flash chromatographed on silica gel using ethyl acetate as eluant to give the title compound as a white solid. MS M^{+1} calculated for $C_{25}H_{42}N_2O_3$, mw = 418.55; observed m/e 419.

Example 14

Preparation of 20-(t-butylaminocarbonyloxy)-410 methyl-5α-4-azapregnap-3-one

Employing substantially the same procedure as described in Example 13, but substituting 20-hydroxy-4-methyl-5 α -4-azapregnan-3-one for the steroid alcohol used therein, the title compound was obtained. MS M⁺¹ calculated for C₂₆H₄₄N₂O₃, mw = 432.65; observed m/e 433.

Example 15

20 Preparation of 17-(methylaminocarbonyloxymethyl)-4methyl-5α-4-azaandrostan-3-one

Employing substantially the same procedure as described in Example 10, but substituting methyl isocyanate and 17-(hydroxymethyl)-4-methyl-5 α -4-azaandrostan-3-one for the benzyl isocyanate and steroid alcohol, respectively, used therein, the title compound was obtained. MS M⁺² calculated for $C_{22}H_{36}N_2O_3$, mw = 376.54; observed m/e 378.

Also included with the scope of this invention are 4-N-X analogs where X is OH, NH₂ or SCH₃. The 4-N-OH and 4-N-NH₂ derivatives can be made by incorporating hydroxylamine or hydrazine, respectively, in place of methyl amine in the seco acid ring A closure for the starting androstanes herein as described in J. Med. Chem. 29, 2998-2315 (1986) by Rasmusson et al. Further, reaction of the anion of the saturated 4-N-H androstanes, wherein the anion is generated from the 4-NH precursor by sodium hydride, and methylsulfenyl chloride can produce the

corresponding 4-N-SCH $_3$ derivative. Thus, substituent ${\tt R}^3$ on the 4-N position also includes OH, NH $_2$ and SCH $_3$.

15

10

5 .

20

25

NMR DATA (ppm)

	Example	Angular Methyls	Miscellaneous
-	1	0.64, 0.88	2.94 (-4-NCH ₃)
5	3 .	0.81, 0.91	1.24 (-SCH(CH ₃) ₂) 1.28
•	48	0.64, 0.90	1.25 (-SCH(CH ₃) ₂) 1.28
10	4b ·	0.64, 0.94	1.22 (-SCH(CH ₃) ₂) 1.26
	5a	0.64, 0.88	2.95 (-4-NCH ₃)
	5b	0.62, 0.86	2.92 (-4-NCH ₃)
15	5c	0.62, 0.87	2.92 (-4-NCH ₃)
. 13	5 đ	0.64, 0.88	2.92 (-4-NCH ₃)
	5e	0.59, 0.88	3.80 (Ph-(OCH ₃) ₂) (Split)
20	5 f	0.65, 0.82	1.22 (Ph-CH(CH ₃) ₂) 1.25
	5 g	0.65, 0.88	3.21 (-SC <u>H</u> ₂ CO ₂ -)
	5h	0.63, 0.88	1.24 (-SCH(CH ₃) ₂) 1.28
25	5 i	0.63, 0.87	1.24 (-SCH(CH ₃) ₂) 1.27
	5 j	0.64, 0.88	1.30 (-C(CH ₃) ₃
	5k	0.64, 0.88	2.92 (-4-NCH ₃)
30	51	0.70, 0.88	1.24 (-SCH(CH ₃) ₂) 1.26

- 43. -

NMR DATA (ppm) con't

	Example	Angular Methyls	Miscellaneous
5	5m	0.63, 0.85	2.89 (-4-NCH ₃)
	5n	0.67, 0.89	2.93 (-4-NC <u>H</u> 3)
	6	0.64, 0.88	2.92 (-4-NC <u>H</u> 3)
	7a	0.64, 0.88	1.02 (-C(CH ₃) ₃)
10	7b	0.64, 0.87	1.13 (-C(CH ₃) ₃)
	7c	0.64, 0.88	3.66 (-co ₂ c <u>H</u> ₃)
	7đ .	0.62, 0.87	5.14 (-0C <u>H</u> 2Ph)
	7e	0.69, 0.88	2.04 (-0COCH ₃)
15	. 7f	0.70, 0.88	1.20 (-C(CH ₃) ₃)
	7g	0.66, 0.90	2.02 (-OCOCH ₃)
	7h	0.68, 0.89	1.18 (-c(c <u>H</u> ₃) ₃)
	8	0.64, 0.94	1.16 (-c(cH ₃) ₃)
20	9	0.62, 0.88	2.94 (-4-NCH ₃)
	10	0.89, 0.92	2.94 (-4-NCH ₃)
	11	0.62, 0.86	2.92 (-4-NCH ₃)
25	13	0.64, 0.86	1.29 (-OCONH-C($C\underline{H}_3$) ₃)
	14	0.69, 0.89	1.32 (-OCONH-C(CH ₃) ₃)
	15	0.67, 0.88	2.78 (-OCONH-CH ₃) 2.82

Novel compounds of the present invention further include, but are not limited to, the following compounds:

5 20-(t-butylaminocarbonyloxy)-4-methyl-5- α -4-aza-pregnan-3-one,

20-(isopropylaminocarbonyloxy)-4-methyl-5- α -4-aza-pregnan-3-one,

10

17-((2-ethylphenylamino)carbonyloxymethyl)-4-methyl-5- α -4-azaandrostan-3-one,

4-methy1-20-(methy1aminocarbony1oxy)-5- α -4-azapregnan-3-one, and

24-(t-butylaminocarbonyloxy)-4-methyl-5- α -4-aza-cholan-3-one.

These compounds can be prepared using substantially the same procedures as described in Example 14, using the appropriate starting materials.

25

Furthermore, the present invention discloses compounds of formula I-a, useful for dually inhibiting both steroid 5α -reductase enzymes 1 and 2 and selectively inhibiting 5α -reductase 1.

5
$$(CHR^{1})_{n}-O-C-R^{4}$$
10
$$\frac{1}{R^{3}}$$

$$\frac{I-a}{R^{3}}$$

wherein:

(I) a is single bond; 15 R^1 is Ħ; \mathbb{R}^3 is -H, methy1, ethy1, -OH, -NH₂, or -SCH₃; an integer selected from 1 through 10; and n is R^4 is -C₁₋₆ alkyl substituted with an 1) unsubstituted phenyl ring, 20 unsubstituted C₅₋₁₀ cycloalky1, 2) 3) unsubstituted phenyl, 4) amino, -C₁₋₈ alkyl substituted amino, or 5)

6 -C₁₋₈ alkoxy;
(II) <u>a</u> is a single bond;

 R^3 is -H; n is zero; and R^4 is $-CH_3$; or

WO 93/23041 PCT/US93/04771

_ 46 _

(III) a is a single bond;

 \mathbb{R}^1 is $-CH_3$;

 R^3 is -H;

n is 1; and

5 \mathbb{R}^4 is $-CH_3$;

or a pharmaceutically acceptable salt or ester thereof.

10

BIOLOGICAL ASSAYS

Preparation of Human prostatic and scalp 5α-reductases

Samples of human tissue were pulverized using a freezer mill and homogenized in 40 mM 15 potassium phosphate, pH 6.5, 5 mM magnesium sulfate, 25 mM potassium chloride, 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol (DTT) containing 0.25 M sucrose using a Potter-Elvehjem homogenizer. A crude nuclear pellet was prepared by centrifugation of the 20 homogenate at 1,500xg for 15 min. The crude nuclear pellet was washed two times and resuspended in two volumes of buffer. Glycerol was added to the resuspended pellet to a final concentration of 20%. The enzyme suspension was frozen in aliquots at 25 -80°C. The prostatic and scalp reductases were stable for at least 4 months when stored under these conditions.

5α -reductase assav.

The reaction mixture contained in a final volume of 100 μl is: 40 mM buffer (human scalp, potassium phosphate, pH 6.5; human prostatic 5. 5α -reductase. sodium citrate, pH 5.5), 0.3-10 μM $^{14}\text{C-T}$ (or $^{3}\text{H-T}$) ("T" stands for testosterone), 1 mM DTT, and 500 µM NADPH. Typically, the assay was initiated by the addition of 50-100 µg prostatic homogenate or 75-200 µg scalp homogenate and 10 incubated at 37°C. After 10-50 min the reaction was quenched by extraction with 250 μ l of a mixture of 70% cyclohexane: 30% ethyl acetate containing 10 µg each DHT and T. The aqueous and organic layers were separated by centrifugation at 14,000 rpm in an 15 Eppendorf microfuge. The organic layer was subjected to normal phase HPLC (10 cm Whatman partisil 5 silica column equilibrated in 1 ml/min 70% cyclohexane: 30% ethyl acetate; retention times: DHT, 6.8-7.2 min; androstanediol, 7.6-8.0 min; T, 9.1-9.7 min). The 20 HPLC system consisted of a Waters Model 680 Gradient System equipped with a Hitachi Model 655A autosampler, Applied Biosystems Model 757 variable UV detector, and a Radiomatic Model Al20 radioactivity The conversion of T to DHT was monitored analyzer. using the radioactivity flow detector by mixing the 25 HPLC effluent with one volume of Flo Scint 1 (Radiomatic). Under the conditions described, the production of DHT was linear for at least 25 min. The only steroids observed with the human prostate 30

and scalp preparations were T, DHT and androstanediol.

Stumptail macaque protocol

The following protocol is utilized with the stumptail macaque monkey to demonstrate the effect of compounds of the present invention for promoting hair growth.

Twenty-one male stumptail macaque monkeys of species Macaca speciosa are assigned to vehicle control and drug treatment groups on the basis of baseline hair weight data. This assignment procedure is necessary to insure that the average baseline hair growth for each control and experimental group is comparable. The control and drug treatment groups are as follows:

15

10

5

- 1. Topical 50:30:20 vehicle (N = 6)
- 2. Oral 5α -reductase and topical 50:30:20 vehicle (N = 5)
- 3. Oral placebo (N = 5)
- 4. 5α -reductase in vehicle (N = 5)

20

25

30

The vehicle consists of 50% propylene glycol, 30% ethanol and 20% water. A 100 mM concentration of topical 5α -reductase is formulated in this vehicle. The same 5α -reductase is administered as an oral dose of 0.5 mg per monkey. Immediately prior to the dosing phase of the study, hair is removed from a 1 inch square area (identified by four tatoos) in the center of the balding scalp. This hair collection is the baseline hair growth determination prior to the beginning of treatment. Approximately 250 μ L of vehicle and 5α -reductase in vehicle is prepared and topically administered to the

10

15

tatooed area of the scalp, The selected 5α -reductase and placebo is ingested by the monkeys at the same time as the topical doses are administered. The monkeys are dosed once per day, seven days per week for twenty weeks.

At four week intervals throughout the dosing phase of the study, each monkey is shaved and the hair is collected and weighed. The body weight data (at baseline and during assay) is analyzed by the monparametric Wilcoxon rank-sum test. Differences are significant at p <0.05. Hair weight data at each week collection for vehicle, placebo and treatment groups are expressed as the change from baseline. Statistical analysis is performed on the rank of the data to show overall differences among groups at each four week collection.

While the invention has been described and illustrated with reference to certain preferred embodiments thereof, those skilled in the art will 20 appreciate that various changes, modifications and substitutions can be made therein without departing from the spirit and scope of the invention. example, effective dosages other than the preferred dosages as set forth herein above may be applicable 25 as a consequence of variations in the responsiveness of the mammal being treated for any of the indications for the compounds of the invention indicated above. Likewise, the specific pharmacological responses observed may vary according 30 to and depending upon the particular active compound selected or whether there are present pharmaceutical carriers, as well as the type of formulation and mode WO 93/23041

- 50 -

of administration employed, and such expected variations or differences in the results are contemplated in accordance with the objects and practices of the present invention. It is intended, therefore, that the invention be limited only by the scope of the claims which follow and that such claims be interpreted as broadly as is reasonable.

10

15

20

25

25

WHAT IS CLAIMED IS:

1. A compound of formula I

10 $(CHR^{1})_{n}-X-C-R^{4}$ $I = \frac{1}{R^{3}}R^{2}$

wherein \underline{a} and \underline{b} are both single bonds and R^2 is hydrogen, or

 \underline{a} is a double bond, \underline{b} is a single bond and R^2 is hydrogen, or

<u>a</u> is a single bond, <u>b</u> is a double bond and \mathbb{R}^2 is absent;

R¹ can be the same or different at each

occurrence when n is greater than 1 and is

selected from: -H, aryl, or $-C_{1-3}$ alkyl unsubstituted or substituted with aryl;

 R^3 is -H, methyl, ethyl, -OH, -NH₂, or -SCH₃;

n is an integer selected from zero through 10;

X is -0- or -S-; and

30 R⁴ is 1) -C₁₋₂₀ alkyl, unsubstituted or substituted with one or more of:

- a) OH
- b) halo,
- c) $-C_{1-8}$ alkoxy,
- d) $-C_{1-6}$ alkenyl,

- e) -CONR⁵R⁵, wherein R⁵ is independently
 - i) -H,
 - ii) -C₁₋₈ alkyl unsubstituted or substituted with one or more of R⁷, aryl or heterocycle, the aryl being unsubstituted or substituted with one or more of R⁷ or R⁹,
 - iii) aryl unsubstituted or substituted with one or more of R⁷ or R⁹, or
 - iv) heterocycle, unsubstituted or substituted with one or more of R⁷ or R⁹,
- f) $-COOR^6$, wherein R^6 is
 - i) -H,
 - ii) -C₁₋₈ alkyl unsubstituted or substituted with one or more of R⁷ or aryl, the aryl being unsubstituted or substituted with one or more of R⁷ or R⁹,
 - iii) ary1, unsubstituted or substituted with one or more of \mathbb{R}^7 or \mathbb{R}^9 .
- g) $-S(0)_D-R^5$, wherein p is zero, 1 or 2;
- $h) -N(R^5)_2,$
- i) aryl, unsubstituted or substituted with one or more of aryl, \mathbb{R}^7 or \mathbb{R}^9 ,
- j) heterocycle, unsubstituted or substituted with one or more of \mathbb{R}^7 or \mathbb{R}^9 .

5 ·

10

15

20

25

			 k) -C₃₋₁₀ cycloalkyl, unsubstituted or substituted with one or more of R⁷ or R⁹, or
			1) -CONR ⁸ -CO-NHR ⁸ , wherein R ⁸ is -H,
. 5			$-C_{1-8}$ alkyl, benzyl or cyclohexyl,
		2)	aryl, unsubstituted or substituted with
			one or more of aryl, R^7 or R^9 ,
		3)	heterocycle or $-C_{3-10}$ cycloalkyl,
10			either of which is unsubstituted or
10			substituted with one or more of \mathbb{R}^7 or \mathbb{R}^9 ,
	•	4).	$-NR^5R^5$, or
		5)	-OR ⁵ ;
			•
15	R^7 is	1)	-OH,
		2)	-C ₁₋₃ alkoxy,
		-	-CN,
		•	-coor6
20		5)	-C ₁₋₈ alky1-COOR ⁶
20	•	6)	$-NO_2$, or
			halo; and
		8)	amino, mono C ₁ -C ₄ alkylamino, di-C ₁ -C ₄ -alkylamino;
25	R^9 is	1)	1-0
٠			substituted with one or more of aryl or \mathbb{R}^7 ,
		2)	-CO-A, $-C_{1-8}$ alkyl-CO-A, -NHCO-A, or
			-S(0) _p -A, wherein p is defined above
30			and A is
	-		a) -H,

30

- b) -C₁₋₈ alky1, unsubstituted or substituted with one or more of
 - $i) \mathbb{R}^7$, or
 - ii) aryl, unsubstituted or substituted with one or more of R⁷, or
- c) aryl, unsubstituted or substituted with one or more of R⁷,
- 3) -NHCO-heterocycle,
- 4) -N(R¹⁰)₂ or -CON(R¹⁰)₂ wherein R¹⁰ is independently, heterocycle or -A,
- 5) -NHCO-(CH₂)_q-CO-Q, wherein q is 1-4, and Q is -N(R¹⁰)₂ or -OR¹⁰;
- with the provisos that:

when n is 1-10, <u>b</u> is a single bond, R^1 is -H at each occurrence, X is -0-, and R^4 is -C₁₋₆alkyl, R^4 is not substituted with an unsubstituted phenyl ring;

when n is 1-10, b is a single bond, R¹ is -H at each occurrence, and X is -0-, R⁴ is not unsubstituted C₅₋₁₀cycloalkyl, unsubstituted phenyl, amino, -C₁₋₈alkyl substituted amino, or -C₁₋₈alkoxy; when n is zero, X is -0-, a and b are both single bonds and R³ is -H, then R⁴ is not -CH₃; and

when n is 1, R^1 is $-CH_3$, X is -0-, <u>a</u> and <u>b</u> are both single bonds, and R^3 is -H, then R^4 is not $-CH_3$;

or a pharmaceutically acceptable salt or ester the thereof.

2. The compound of Claim 1 having structural formula II

5

10

3. The compound of Claim 2 wherein \mathbb{R}^4 is $-C_{1-20}$ alkyl, unsubstituted or substituted with one or more of

-OH, halo, $-C_{1-8}$ alkoxy, $-C_{1-6}$ alkeny1, $-S(0)_p - R^5$, $-N(R^5)_2$, aryl unsubstituted or substituted with one or more of aryl, R^7 or R^9 , heterocycle unsubstituted or substituted with one or more of R^7 or R^9 , or $-C_{3-10}$ cycloalkyl unsubstituted or substituted with one or more of R^7 or R^9 .

- 25 4. The compound of Claim 2 wherein R^4 is $-C_{1-20}$ alkyl substituted with $-CONR^5R^5$, $-COOR^6$ or $-CONR^8CONHR^8$.
- 5. The compound of Claim 2 wherein R⁴ is aryl unsubstituted or substituted with one or more of aryl, R⁷ or R⁹;

heterocycle unsubstituted or substituted with one or more of R⁷ or R⁹;

 $-C_{3-10}$ cycloalkyl unsubstituted or substituted with one or more of R^7 or R^9 ; $-NR^5R^5$; or $-0R^5$.

6. The compound of Claim 1 having structural formula III

7. The compound of Claim 6 wherein \mathbb{R}^4 is $-C_{1-20}$ alkyl, unsubstituted or substituted with one or more of

-OH, halo, $-C_{1-8}$ alkoxy, $-C_{1-6}$ alkenyl, $-S(0)_p - R^5$, $-N(R^5)_2$, aryl unsubstituted or substituted with one or more of aryl, R^7 or R^9 , heterocycle unsubstituted or substituted with one or more of R^7 or R^9 , or $-C_{3-10}$ cycloalkyl unsubstituted or substituted with one or more of R^7 or R^9 .

8. The compound of Claim 6 wherein R^4 is $-C_{1-20}$ alkyl substituted with $-CONR^5R^5$, $-COOR^6$ or $-CONR^8CONHR^8$.

9. The compound of Claim 6 wherein \mathbb{R}^4 is any unsubstituted or substituted with one or more of any 1, \mathbb{R}^7 or \mathbb{R}^9 ;

heterocycle unsubstituted or substituted with one or more of R⁷ or R⁹;

 $-C_{3-10}$ cycloalkyl unsubstituted or substituted with one or more of R^7 or R^9 ; $-NR^5R^5$; or $-0R^5$.

- 10. A compound selected from the group consisting of:
 - 20-(11-(ethylthio)undecanoyloxy)-4-methyl-5 α -4-azapregnan-3-one,
- 20-ethoxyacetyloxy-4-methyl-5 α -4-azapregnan-3-one, 17-(12-(isopropylthio)dodecanoyloxy)-4-methyl-5 α -4-azaandrostan-3-one,
 - 20-(12-(isopropylthio)-dodecanoyloxy)-5 α 4-azapregn-1-ene-3-one,
- 17-acetyloxymethyl-4-methyl-5α-4-azaandrostan-3-one,
 4-methyl-20-tridecanoyloxy-5α-4-azapregnan-3-one,
 20-t-butylacetyloxy-4-methyl-5α-4-azapregnan-3-one,
 4-methyl-20-trimethylacetyloxy-5α-4-azapregnan-3-one,
 4-methyl-20-(10-undecenoyloxy)-5α-4-azapregnan-3-one,
- 25 20-(3,7-dimethy1-6-octenoyloxy)-4-methy1-5α-aza-pregnan-3-one,
 - 20-(3-carboxypropionyloxy)-4-methyl-5 α -4-azapregnan-3-one,
- 20-(11-(carbomethoxy)undecanoyloxy)-4-methy1-5 α -4azapregnan-3-one,
 - 20-(3-(carbobenzyloxy)propionyloxy)-4-methy1-5 α -4-azapregnan-3-one,
 - 20-(1-adamanty1acety1oxy)-4-methy1-5 α -4-azapregnan-3-one

- 4-methy1-20-(2-norborny1acety1oxy)-5 α -4-azapregnan-3-one,
- 20-(3,4-dimethoxyphenyl)acetyloxy-4-methyl-5 α -4-aza-pregnan-3-one,
- 5 20-(4-isopropylphenyl)acetyloxy-4-methyl-5α-4-aza pregnan-3-one
 - 20-(isopropylthio)acetyloxy-4-methyl-5α-4-azapregnan-3-one,
- 20-(9-(isopropylthio)nonanoyloxy)-4-methy1-5α-4-azapregnan-3-one,
 - 20-(12-(isopropylthio)dodecanoyloxy)-4-methyl-5 α -4-azapregnan-3-one,
 - 20-(11-(ethylsulfinyl)undecanoyloxy)-4-methyl-5 α -4-azapregnan-3-one,
- 20-(12-(t-butylthio)dodecanoyloxy)-4-methyl-5α-4-azapregnan-3-one
 - 4-methy1-20-(4-thien-2-y1)butyryloxy-5 α -4-aza-pregnan-3-one,
 - 20-trimethylacetyloxy- 5α -4-azapregnan-3-one,
- 20 20-(9-(isopropylthio)nonanoyloxy)-5 α -4-azapregnan-3-one,
 - 20-(12-(isopropylthio)dodecanoyloxy)- 5α -4-azapregnan-3-one,
 - 20-acetoxymethy1-4-methy1-5 α -4-azapregnan-3-one,
- 4-methy1-20-(trimethy1acety1oxy)methy1-5α-4-azapregnan-3-one,
 - 20-(12-(isopropylthio)dodecanoyloxy)methyl-4-methyl- 5α -4-azapregnan-3-one,
- 4-methyl-17-trimethylacetyloxymethyl-5 α -4azaandrostan-3-one,
 - 17-(2-ethylhexanoyloxy)methyl-4-methyl-5 α -4-azaandrostan3-one,

17-(12-(isopropylthio)dodecanoyloxy)methyl-4-methyl- 5α -4-azaandrostan-3-one,

17B-(benzylaminocarbonyloxy)-4-methyl-5 α -4-azaandrostan-3-one, and

5 20-trimethylacetyloxy- 5α -4-azapregn-1-ene-3-one,

or a pharmaceutically acceptable salt or ester thereof.

10 11. A compound of formula I-a

wherein:

(I) a is a single or double bond;

 R^1 is -H:

30

R³ is -H, methyl, ethyl, -OH, -NH₂, or -SCH₃; n is an integer seleted from 1 through 10; and

R⁴ is 1) -C₁₋₆ alkyl substituted with an unsubstituted phenyl ring.

2) unsubstituted C₅₋₁₀ cycloalky1,

3) unsubstituted phenyl,

4) amino,

5). $-C_{1-8}$ alkyl substituted amino, or

6 $-C_{1-8}$ alkoxy;

(II) a is a single bond; R^3 is -H: n is zero; and R^4 is -CH3; or 5 (III) a is a single bond; R^1 is -CH2; R^3 is -H; nis 1; and 10 R⁴ is -CH2;

or a pharmaceutically acceptable salt or ester thereof.

- 12. A compound selected from the group consisting of:
 - 17-(t-butylaminocarbonyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one,
- 17-(methylaminocarbonyloxymethyl)-4-methyl-5 α -4-azaandrostan-3-one, and 20-(t-butylaminocarbonyloxy)-4-methyl-5 α -4-
- or a pharmaceutically acceptable salt or ester thereof.

azapregnan-3-one,

13. A compound selected from the group consisting of:

20-(t-butylaminocarbonyloxy)-4-methyl-5- α -4-azapregnan-3-one,

20-(isopropylaminocarbonyloxy)-4-methyl-5- α -4-aza-pregnan-3-one,

10 17-((2-ethylphenylamino)carbonyloxymethyl)-4-methyl- $5-\alpha-4$ -azaandrostan-3-one,

4-methyl-20-(methylaminocarbonyloxy)-5- α -4-aza-pregnan-3-one, and

15

24-(t-butylaminocarbonyloxy)-4-methy1-5- α -4-aza-cholan-3-one,

or a pharmaceutically acceptable salt thereof.

20

14. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 in a pharmaceutically acceptable carrier therefor.

- 15. The use of a compound of Claim 1 for the preparation of a medicament useful for treating benign prostatic hyperplasia, acne, female hirsutism, male pattern baldness, androgenic alopecia,
- prostatitis, and/or preventing prostatic carcinoma in a human host in need of such treatment.

- 16. The method of Claim 15 wherein said compound is an inhibitor of 5α -reductase 1.
- 17. The method of Claim 15 wherein said compound is an inhibitor of 5α -reductase 2.
 - 18. The method of Claim 15 wherein said compound is a dual inhibitor of both $5\alpha\text{--reductase 1}$ and 2.

15

20

25

INTERNATIONAL SEARCH REPORT

International application No. PCT/US93/04771

PPC(5) :A61K 31/435 COTD 221/02	A. CLA	SSIFICATION OF SUBJECT MATTER		
SECOND SEARCHED Minimum documentation searched (classification system followed by classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: ASIK 31/470 Documentation searched other than minimum documentation to the extent that such documenta are included in the fields searched classification system followed by classification symbols) U.S.: ASIK 31/470 Documentation searched other than minimum documentation to the extent that such documenta are included in the fields searched classification system for the search form of the searc	IPC(5)	:A61K 31/435 C07D 221/02		•
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S.: AGIK 31/470 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched (classification system) Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online Structure Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim N Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, parabridging cols 1-2, last 3 lines. See entire document. J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Further documents are listed in the continuation of Box C. See patient family annex. Special designers of the discussion of the structure in the international filing data on the part of purcular relevance to existed a service of purcular relevance to claim and the patients and so docubed relation or other second or the second of the	US CL	:546/77; 514/284	•	•
Minimum documentation searched (classification system followed by classification symbols) U.S.: ASIK 31/470 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched classification symbols are consulted during the international search (name of data base and, where practicable, search terms used) CAS Online Structure Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim N Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase inhibitor, alone and in combination with Topical Minoxidili in the Balding Stumptial Macaque, pages 345-350. See page 345, parabridging cols 1-2, last 3 lines. See entire document. J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special designers of and electromers are listed in the continuation of Box C. See patent family annex. Special designers of a such release to an order decidence or other visible to grow and principle for theory underlying the terrosical section of such as a forest continuation of the continuation of Box C. See patent family annex. See p	According t	to International Patent Classification (IPC) or to b	oth national classification and IPC	
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online Structure Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Pelevant to claim N Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al., "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special companies of chard documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. See psicnt family annex. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document with the process of the second of the continuation of Box C. Further documents are listed in the continuation of Box C. See psicnt family annex. Special companies of chard documents are included with the second difference of the continuation of the	B. FIEI	LDS SEARCHED		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online Structure Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Citation of document, with indication, where appropriate, of the relevant passages Pelevant to claim N Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al., "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special companies of chard documents are listed in the continuation of Box C. Further documents are listed in the continuation of Box C. See psicnt family annex. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document with the process of the second of the continuation of Box C. Further documents are listed in the continuation of Box C. See psicnt family annex. Special companies of chard documents are included with the second difference of the continuation of the	Minimum d	ocumentation searched (classification system follo	wed by classification exphale)	
Decumentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online Structure Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages A al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidli in the Balding Stumptall Macaque, pages 345-350. See page 345, para, bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. **Special casegories of dead decrease: **Journal of premate raises of date an visible is not considered to be per of premate raises and of acceptance of the continuation of Box C. **Special casegories of dead decrease: **Journal of premate raises of date and visible is not considered to be per of premate raises and of acceptance of premate raises and the second continuation of Box C. **Special casegories of dead decreases: **Journal of the premate raises of date and visible is not considered to be per of premate raises of acceptance of premate raises of acceptance of premate raises of acceptance on the date of acceptance	U.S. ;	A61K 31/470	by callstacedon symbols)	•
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online Structure Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim N Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special casegories of cited documents Special casegories of cited documents artier document patibilised on or where the international filing date or principle internation to be part of personals released on the principle internation of personals released on the principle internation of personal released on the principle internation of personal released on the principle internation of personal released in the continuation of document platified on or where the international filing date or principle internation to personal released on the principle internation of personal released on the continuation of personal released on the principle internation of personal released on the continuation of personal released on the continuation of personal released on the continuation of the continuation of personal released on the continuation of per				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS Online Structure Search C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim N Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special casegories of cited documents Special casegories of cited documents artier document patibilised on or where the international filing date or principle internation to be part of personals released on the principle internation of personals released on the principle internation of personal released on the principle internation of personal released on the principle internation of personal released in the continuation of document platified on or where the international filing date or principle internation to personal released on the principle internation of personal released on the continuation of personal released on the principle internation of personal released on the continuation of personal released on the continuation of personal released on the continuation of the continuation of personal released on the continuation of per	Documentat	ion searched other than minimum documentation to		
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages A Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. **Topical categories of chal documents** **Journal of particular relevance of the art which is not considered to be part of particular relevance cannot be document which says there doubt on or after the interresional filling data. **Topical categories of chall documents which says there doubt on or after the interresional filling data. **Comment which says there doubt on or after the interresional filling data completed in the publication date of another citation or other substitution in publication of the interresional filling data completed in the publication of the interresional filling data completed in the publication of the interresional filling data completed in the publication of the interresional filling data completed in the continuation of the interresional filling data completed in the continuation of the interresional filling data completed in or the interresional filling data completed in the continuation of the interresional filling data completed in or the interresional filling data but have the considerable in wronice cannot be being objective to a server and intervention and the server in the continuation of the interresional filling data completed in the continuation of the interresional filling data completed in the continuation of the interresional search report 31 JULY 1993 The analysis of the interresional filling data but share than the continuational search report 32 JULY 1993		The state of the s	the extent that such documents are included	in the fields searched
C. DOCUMENTS CONSIDERED TO BE RELEVANT A. JOUR, Clinical Endoc, and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A. J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. C. Document. Special casegories of sked documents are listed in the continuation of Box C. See patent family annex. See patent family annex. To document defining the greenial area of the an which is not considered to be part of purcular relevance and the second continuation of the policial part of the second continuation of the part of purcular relevance and continuation of the policial part of the second continuation of the policial part of the second continuation of the second continuation of the policial part of the second continuation of the second continuation of the policial part of the second continuation of the international fling date of the second continuation of the international fling date but have the second continuation of the international fling date but have the second continuation of the international fling date but have the second continuation of the international fling date but have the second continuation of the international search report To the second continuation of the international search report 31 JULY 1993 Authorized offlicer D. G. DAUS D. DOCUMENT TO SERVE TO SERVE TO SERVE TO SERVE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT A. JOUR, Clinical Endoc, and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A. J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. C. Document. Special casegories of sked documents are listed in the continuation of Box C. See patent family annex. See patent family annex. To document defining the greenial area of the an which is not considered to be part of purcular relevance and the second continuation of the policial part of the second continuation of the part of purcular relevance and continuation of the policial part of the second continuation of the policial part of the second continuation of the second continuation of the policial part of the second continuation of the second continuation of the policial part of the second continuation of the international fling date of the second continuation of the international fling date but have the second continuation of the international fling date but have the second continuation of the international fling date but have the second continuation of the international fling date but have the second continuation of the international search report To the second continuation of the international search report 31 JULY 1993 Authorized offlicer D. G. DAUS D. DOCUMENT TO SERVE TO SERVE TO SERVE TO SERVE	Electronic d	ata base consulted during the international		
C. DOCUMENTS CONSIDERED TO BE RELEVANT Category* Citation of document, with indication, where appropriate, of the relevant passages A Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al., "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para, bridging cols 1-2, last 3 lines. See entire document. J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special casegories of cital documents: Special casegories of cital documents: Special casegories of cital documents: Special casegories of cital documents are listed in the continuation of Box C. See patent family annex. **A*	CAS Onli	ing Structure County	(name of data base and, where practicable	, search terms used)
Category* Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim N Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special casegories of class decreases:	ONO OIM	me Strocture Search		
Category* Citation of document, with indication, where appropriate, of the relevant passages A Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. **Special casegories of closel documents.** **Special casegories of closel documents.** **Jectual casegories of closel				
Category* Citation of document, with indication, where appropriate, of the relevant passages Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al., "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE' PAGES 1442-6. See entire document. Special categories of cited document: 'You document defining the present leave of the an which is not considered to be part of pursualty relevance; the chismed invention cannot be received accument published on or after the international filing date." Special categories of cited documents: 'You document published the propriety of the any which is not occasioned to be part of pursualty relevance; the chismed inventions cannot be received and any throw doubts on printing chism(s) or which is cled to canabish the published on or after the international filing date. 'You document published study throw doubt on printing chism(s) or which is cled to canabish the published study of the constitution formed or cannot be received and the constitution of the constituti	C. DOC	UMENTS CONSIDERED TO BE DELEVADO		
Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special consequence of clear documents: document of clear documents: document which may three departments clear to make the publication date of acother cisation or which is cited to emake the publication date of acother cisation or which is the privace trapes of the proprial research trapes or some consequence of acother which are three trapes or the considered with any three departments or special research to provide the provider control to be part of purchase referring to so and disclosure, use, exhibition or other memory and acoustic of the control of the international search the privacy documents published prior to the international search the privacy acontrol of the international search the privacy acontrol of the international search and the privacy acontrol of the international search Journal of the actual completion of the international search The privacy acontrol of the privace of the p				•
Jour. Clinical Endoc. and METAB., Vol. 74 1992, Diani et al. "HAIR GROWTH EFFECTS OF ORAL ADMINISTRATION OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidil in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTERIDL LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special caegories of cital document. Special caegories of cital document. Special caegories of cital document. See an active document are listed in the continuation of Box C. See patent family annex. See entire document published and the service of the an which is not considered to be part of percular relevance. Lastier document published on or after the international filing date document which say throw docks as priority chaired; to which is a consultation of the comment of percular relevance; the chaired is environment to septimize the document in such on document and document referring to as oral disclosure, use, chibition or other document published prior to the international search document and document referring to as oral disclosure, use, chibition or other document published prior to the international search document and document referring to as oral disclosure, use, chibition or other document published prior to the international search and document referring to as oral disclosure, use, chibition or other document published prior to the international search report and document published prior to the international search report and document published prior to the international search report and document published prior to the international search report and document published prior to the international search report and document published prior to the international search report and document published prior to the international search report and document published prior to the international search report and the published prior	Category*	Citation of document, with indication, where	appropriate, of the relevant passages	Delevent to all 1
Further documents are listed in the continuation of Box C. See patent family annex.				Astevant to claim No.
OF FINASTERIDE, A, steroid 5 Reductase Inhibitor, alone and in combination with Topical Minoxidll in the Balding Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special case griss of cited documenar: document defining the present state of the six which is not considered to be part of pursuals relevance as a considered to be part of pursuals relevance can specified be considered to the published prior to the international filing data changes of published prior to the international filing data changes of published prior to the international filing data but be reviewed to the published prior to the international filing data but be reviewed to the published prior to the international filing data but be reviewed to the published prior to the international filing data but be reviewed to the published prior to the international filing data but be reviewed to the published prior to the international filing data but but the priority claims of published prior to the international filing data but be reviewed to the published prior to the international filing data but but the published prior to the international filing data but but the published prior to the international filing data but but the published prior to the international filing data but but the published prior to the international search To the actual completion of the international search 21 July 1993 The and mailing address of the ISA/US commissioner of Peticus and Trademarks Authorized officer D. G. DAUS Authorized officer D. G. DAUS	. [Jour. Clinical Endoc. and META	B., Vol. 74 1992 Diani et	15.19
A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE' PAGES 1442-6. See entire document. Special casegories of cited documents. **Total document defining the present state of the an which is not considered to be part of purcular retervance: cardior document referring to as oral disclosure, use. exhibition or other more and maximing address of the ISA/US commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of the ISA/US commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of the ISA/US commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 1931 **Total commissioner of Patents and Trademarks on PCT Abbit 193	A	OF TAIN GROWIN EFFECTS O	F ORAL ADMINISTRATION!	13-10
Stumptail Macaque, pages 345-350. See page 345, para. bridging cols 1-2, last 3 lines. See entire document. A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE" PAGES 1442-6. See entire document. Special casegories of cited documents: document defining the general state of the art which is not considered to be part of purcular relevance; and of purcular relevance are document which sure therefore the entire state of the continuation of which is cited to considered the specifical control of the document which sure throw double on priority claim(s) or which is cited to consider the specifical control of the state of accument a published prior to the international filing date to considered above or cannot be considered to involve an investment and the priority data claimed to the part of the same of the state of accument is falled and the control of particular relevance; the chiamed investor cannot be considered to involve an investment and the priority data chiamed to the priority data chiamed to the priority claim(s) or which is cited to considered to involve an investment and consumers and provided with involve an investment and consument and priority or the same particular relevance; the chiamed investors cannot be considered to involve an investment and consument and the priority data chiamed to the considered to involve an investment and consument and the priority data chiamed the control of particular relevance; the chiamed investors and consument and the priority data chiamed to the considered of particular relevance; the chiamed investors and consument and the priority data chiamed to the considered of particular relevance; the chiamed investors and consument and the priority data chiamed to the considered of particular relevance; the chiamed investors and considered and the priority data chiamed to be priority chiamed to the considered and the particular relevance; the chiamed investors and considered and consument and consument and consume	l	OF FINAS IERIDE, A. steroid 5	Reductase Inhibitor along	
A J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE' PAGES 1442-6. See entire document. J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE' PAGES 1442-6. See entire document. J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE' PAGES 1442-6. See entire document of the control of th	ł	and in combination with Topic	al Minoxidil in the Boldine	
J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE' PAGES 1442-6. See entire document are listed in the continuation of Box C. See patent family annex. Special casegories of cited documents: document defaning the general state of the art which is not considered to be part of parameter relevance: cartier document published on or after the international filing date document which say throw doubts on priority chain(s) or which is cited to canadian the publication date of another citation or other special reason (as specified) document published prior to the international filing date but later than the priority date chained and comment published prior to the international filing date but later than the priority date chained The priority date chained The priority date chained The priority date chained The priority date chained inventor cannot be considered to involve an inventor step when the document in all the priority of the international search The priority date chained inventor cannot be considered to involve an inventor step when the document in all the priority date chained The priority date chained The priority date chained inventor cannot be considered to involve an inventor step when the document in all the priority of the international search The priority date chained The priority date chained The priority date chained inventor cannot be considered to involve an inventor and combined with one or or more other such documents, such combined with one or or more other such documents, such combined with one or or more other such documents, such combined with one or or more other such documents, such combined with one or or more other such documents, such combined with one or or more other such documents, such combined with one or or more other such documents, such combined with one or or or other such documents, such combined with one or or or other such documents, such combined with one or or or other such documents, such combined wi		Stumptan Wacaque, Dages 345.		
J. ORG. CHEM. Vol. 46, 1981, BACK "OXIDATION OF AZASTEROID LASCTASMS AND ALCOHOLS WITH BENZENESELENIC ANHYDRIDE' PAGES 1442-6. See entire document of civil documents. Special categories of civil documents: document defining the general state of the srt which is not considered to be part of purcular relevance: curlier document published on or after the international filing date of considered which say throw doubts on priority chain(s) or which is closed to cambilate the publication date of acother ciscion or other special reason (see spec	İ	bridging cols 1-2, last 3 lines. S	ee entire document	·
Further documents are listed in the continuation of Box C. Special categories of cited documents: document defining the general sease of the art which is not considered to be part of purposition related to a rather the international filing date or which is channel to emblish the publication date of another citation or other document published on or after the international filing date or principle or theory underlying the invention cannot be considered to emblish the publication date of another citation or other another referring to an oral disclosure, use, exhibition or other measure document published prior to the international filing date but later than document published prior to the international filing date but later than the priority date claimed document published prior to the international filing date or proving date and so in conflict with the application but each to understand the principle or theory underlying these in conflicts with the application but each to understand the considered to involve an averance supplication but each to understand the considered to involve an averance supplication but each to understand the considered to involve an averance supplication but each to understand the considered to involve an averance supplication but and accument in subsect and comments and comments and comments are document in subsect and averance supplication but and the surface of particular relevance; the claimed inversion cannot be considered to involve an investory step when the document member of the same patcot family document published prior to the international search 3 JULY 1993 Date of mailing of the international search particular relevance; the claimed inversion cannot be considered to involve an investory step when the document member of the same patcot family document published prior to the international search 2 July 1993 Date of mailing address of the ISA/US Oranniasioner of Patents and Trademarks Oranniasioner of Patents and Trademarks Oranniasioner of Patents and Trademarks O				
Further documents are listed in the continuation of Box C. See patent family annex. Special categories of cited documents: document defining the general state of the an which is not considered to be part of purcular relevance to the part of purcular relevance and the surveition of cited to combinate the publication date of another citation or other document published on or after the international filing date. document referring to an oral disclosure, use, exhibition or other measure and comments referring to the international filing date but later than the principle document in which also the publication date of another citation or other measures and comments referring to the another international filing date but later than the principle document in which also the document in which also documents referring to the international filing date but later than the principle document of particular relevance; the chained inversion cannot be considered to involve an inventory step when the document is an aversarive step when the document in early of the considered to involve an inventory step when the document in the accomment in the principle or theory underlying the invention cannot be considered to involve an inventory step when the document in the accomment in the considered to involve an inventory step when the document and the considered to involve an inventory step when the document in the document in the document in the document in the document and the principle or theory underlying the international inventory cannot be considered to involve an inventory step when the document in the document in the document in the principle or theory underlying the international the principle or theory underlying the international the principle or theory underlying the considered to involve an inventory step when the document of particular relevance; the chained inventory cannot be considered to involve an inventory step when the document of particular relevance; the chained inventory cannot be considered to involve an inven	A	J. ORG. CHEM. Vol. 46, 198		
BENZENESELENIC ANHYDRIDE' PAGES 1442-6. See entire Comment		AZASTEROID LASCTASMS	1-18	
Further documents are listed in the continuation of Box C. Special casegories of cited documents: 'T document defining the general state of the art which is not considered to be part of particular relevance confidence and not in conflict with the application but cared to understand the principle or theory underlying the invention cannot be considered above on priority chain(s) or which is cited to emblish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other money. document published prior to the international filing date but later than the priority date claimed inventor cannot be considered to priority date claimed inventor cannot be considered to proving the claimed inventor cannot be considered to proving the claimed inventor cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor or cannot be considered to proving the claimed inventor cannot be considered to proving the constant of particular relevance; the claimed inventor cannot be considered to proving the constant of particular relevance; the claimed inventor cannot be considered to proving the proving the considered to proving the provi	ł		PACES 1442 C. S.	•
See patent family annex. Special casegories of cited documents: document defining the general state of the art which is not considered to be part of particular relevance: critic document published after the international filing date or proving date and not in conflict with the application but cited to understand the principle or theory underlying the averation cannot be considered to emblate the publication date of another citation or other operation cannot be considered to involve an inventive and occurrent published prior to the international filing date or which is cited to emblate the publication date of another citation or other operation considered to involve an inventive and occurrent published prior to the international filing date but later than the priority date claimed invention or other occurrent published prior to the international filing date but later than the priority date claimed. Date of mailing of the international search report and address of the ISA/US commissioner of Patents and Trademarks to RPT. Authorized officer D. G. DAUS Description of the international filing date but later than the priority date claimed. Authorized officer D. G. DAUS Description of family annex. The later documents published after the international filing date or priority date claimed invention of the internation of another citation of the international filing date or thinks in conflict with the international invention cannot be combined which one or more other such documents invention of combined with one or more other such documents in the document is such alone. The later documents published after the international filing date or priority in the invention of the inve		document.	rages 1442-6. See entire	
Special categories of cited documents: The state of document published after the international filing date or priority date and not in conflict with the application but end to understand the principle or theory underlying the suvention of cartier document published on or after the international filing date or priority claims) or which is cited to cambish the publication date of another citation or other special reason (as specified) The document referring to an oral disclosure, use, exhibition or other means document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report Journal of particular relevance; the claimed inventor cannot be considered to involve an inventive step when the document is maken alone considered to involve an inventive step when the document is maken alone considered to involve an inventive step when the document is combined with one or more other such document is a maken alone considered to involve an inventive step when the document is maken alone considered to involve an inventive step when the document is maken alone considered to involve an inventive step when the document is maken alone. The published after the international invention that invention the invention of inventive and invention to involve an inventive step when the document is maken alone. The principle or theory underlying the invention of inventive step when the document is maken alone. The document of particular relevance; the claimed invention to considered novel or cannot be considered to involve an inventive step when the document is maken alone. The principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step co	İ			
Special casegories of cited documents: document defining the general state of the art which is not considered to be part of purcular relevance: carlier document published on or after the international filing date carlier document which may throw doubts on priority claim(s) or which is cited to enablish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed document published after the international filing date or priority date and not in conflict with the application but end to understand the priority date claimed invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered novel or cann			}	
Special casegories of cited documents: document defining the general state of the art which is not considered to be part of purcular relevance: carlier document published on or after the international filing date carlier document which may throw doubts on priority claim(s) or which is cited to enablish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed document published after the international filing date or priority date and not in conflict with the application but end to understand the priority date claimed invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered novel or cann				
Special casegories of cited documents: document defining the general state of the art which is not considered to be part of particular relevance: cartier document published on or after the international filing date cartier document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed document published after the international filing date or priority date and not in conflict with the application but end to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is maken alone combined with one or more other such document is combination being obvious to a person skilled in the art document published after the international filing date or priority date and not in conflict with the application but ended to understand the principle or theory underlying the invention teamont be considered novel or cannot be considered nove				
Special categories of cited documents: The state of document published after the international filing date or priority date and not in conflict with the application but end to understand the principle or theory underlying the suvention of cartier document published on or after the international filing date or priority claims) or which is cited to cambish the publication date of another citation or other special reason (as specified) The document referring to an oral disclosure, use, exhibition or other means document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed Date of the actual completion of the international search Date of mailing of the international search report Journal of particular relevance; the claimed inventor cannot be considered to involve an inventive step when the document is maken alone considered to involve an inventive step when the document is maken alone considered to involve an inventive step when the document is combined with one or more other such document is a maken alone considered to involve an inventive step when the document is maken alone considered to involve an inventive step when the document is maken alone considered to involve an inventive step when the document is maken alone. The published after the international invention that invention the invention of inventive and invention to involve an inventive step when the document is maken alone. The principle or theory underlying the invention of inventive step when the document is maken alone. The document of particular relevance; the claimed invention to considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is maken alone. The principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step co				
Special casegories of cited documents: document defining the general state of the art which is not considered to be part of purcular relevance: carlier document published on or after the international filing date carlier document which may throw doubts on priority claim(s) or which is cited to enablish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed document published after the international filing date or priority date and not in conflict with the application but end to understand the priority date claimed invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered novel or cann	1	•		
Special casegories of cited documents: document defining the general state of the art which is not considered to be part of purcular relevance: carlier document published on or after the international filing date carlier document which may throw doubts on priority claim(s) or which is cited to enablish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed document published after the international filing date or priority date and not in conflict with the application but end to understand the priority date claimed invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is maken alone "Y" document of particular relevance; the claimed invention cannot be considered novel or cann			Ī	
Special categories of cited documents: document defining the general state of the art which is not considered to be part of particular relevance: carlier document published on or after the international filing date document published on or after the international filing date or priority date and not in conflict with the application but end to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is after the international invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is after the international invention but end to understand the principle or theory underlying the invention cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered novel or cannot be considered to involve an inventive step when the document is after the internation is maken alone. "Y" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventor such as a particular relevance; t				
Special casegories of cited documents: document defining the general state of the art which is not considered to be part of particular relevance or cartier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to enablish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed document referring to the international filing date but later than the priority date claimed Date of mailing of the international search report 3 JULY 1993 Authorized officer D. G. DAUS Authorized deficient with the application date or priority date and not in conflict with the application but cited to understand the priority in the servation cannot be considered to involve an inventore step when the document of particular relevance; the claimed inventor cannot be considered to involve an inventore step when the document of particular relevance; the claimed inventor cannot be considered to involve an inventore step when the document is taken alone "Y" document published after the international filing date or priority date and not in conflict with the application but cited to understand the priority in the servation of the inventor cannot be considered as over or cannot be considered to involve an inventor extent and the document of particular relevance; the claimed inventor cannot be considered to involve an inventor extent of particular relevance; the claimed inventor cannot be considered to involve an inventor extent of particular relevance; the claimed inventor cannot be considered to involve an inventor extent of particular relevance; the claimed inventor cannot be considered to involve an inventor extent of particular relevance; the claimed inventor and considered to involve an inventor extent of particular relevance; the claimed inventor extent of partic	X Further	documents are listed in the continuation of Box	C. See patent family appex	
document defining the general state of the art which is not considered to be part of purucular relevance carlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed to of the actual completion of the international search Date of mailing of the international search report 3 JULY 1993 Authorized officer		al categories of cited documents:		·
carlier document published on or after the international filing date document which may throw doubts on priority claims(s) or which is cited to emblish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed document published prior to the international filing date but later than the priority date claimed Date of mailing of the international search report 3 JULY 1993 Authorized officer Authorized officer Authorized officer D. G. DAUS Authorized Serving the invention cannot be considered novel or cannot be considered novel or considered novel or cannot be considered novel o		nest defining the general state of the art which is not considered	date and not in conflict with the application	to be to amount the second to the second
document which may throw doubte on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed document published prior to the international filing date but later than the priority date claimed Date of mailing of the international search particular relevance: the claimed inventors cannot be considered to involve an inventore step when the document is maken alone document of particular relevance: the claimed inventors cannot be considered to involve an inventore step when the document is maken alone document of particular relevance: the claimed inventors cannot be considered to involve an inventore step when the document is maken alone document of particular relevance: the claimed inventors cannot be considered to involve an inventore step when the document is maken alone document of particular relevance: the claimed inventors considered to involve an inventore step when the document is maken alone document of particular relevance: the claimed inventors:		here of branching testables	hammer or enemy emotalisms the statem	906
cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed the of the actual completion of the international search 3 JULY 1993 The and mailing address of the ISA/US commissioner of Patents and Trademarks Authorized officer Vashington, D.C. 20231 Sesimile No. NOT APPLICABLE To document in axion associated association or other considered to involve an inventore step when the document is considered to involve an inventore step when the document is considered to involve an inventore step when the document is considered to involve an inventore step when the document is considered to involve an inventore step when the document is considered to involve an inventore step when the document is considered to involve an inventore step when the document is considered to involve an inventore step when the document is considered to involve an inventore step when the document is axion associated to involve an inventore step when the document is axion associated to involve an inventore step when the document is axion associated to involve an inventore step when the document is axion associated to involve an inventore step when the document is axion associated to involve an inventore step when the document is axion associated to involve an inventore step when the document is axion associated to involve an inventore step when the document is axion associated to involve an inventore step when the document is axion associated to involve an involve an involve an inventore step when the document is axion associated to involve an involve an involve an involve an involve an involve an involve an involve an involve and the document is axion associated to involve an involve an involve and involve an involve an involve an involve an involve an involve an involve and involve and involve an involve an involve an involve a			considered povel or cappet he considered	laimed invention cannot be
document referring to an oral disclosure, use, exhibition or other means document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed the of the actual completion of the international search 3 JULY 1993 The and mailing address of the ISA/US commissioner of Patents and Trademarks Authorized officer D. G. DAUS Occurrent of particular relevance; the claimed invention cannot be considered to involve an invention state when the document of combination being obvious to a person skilled in the art document member of the same patent family Authorized of mailing of the international search report 3 JULY 1993 Authorized officer D. G. DAUS D. G. DAUS	-	TO CHARLES THE DUDICATION date of another aircin.	A STATE OF CHESTER IN SECTION STORE	•
document published prior to the international filing date but later than the priority date claimed document published prior to the international filing date but later than the priority date claimed a document member of the same patent family Date of mailing of the international search report 3 JULY 1993 The and mailing address of the ISA/US Commissioner of Patents and Trademarks D. G. DAUS Authorized officer Vashington, D.C. 20231 D. G. DAUS D. G. DAUS	7	(as specusor)		himed invention cannot be
document published prior to the international filing date but later than the priority date claimed "&" document member of the same patent family document member of the same patent family Date of mailing of the international search report 3 JULY 1993 The and mailing address of the ISA/US Commissioner of Patents and Trademarks Low PCT Vashington, D.C. 20231 Sesimile No. NOT APPLICABLE	Thomas	seas reserring to an oral disclosure, use, exhibition or other	WALLEY AND COL OF MOSE GOOD BY A	
the of the actual completion of the international search 3 JULY 1993 The and mailing address of the ISA/US Commissioner of Patents and Trademarks Tox PCT Vashington, D.C. 20231 Description of the international search report Date of mailing of the international search report Authorized officer D. G. DAUS D. G. DAUS D. G. DAUS		cut published prior to the international filing date but later than	sound on some as a beautiful section as the s	n
The and mailing address of the ISA/US Commissioner of Patents and Trademarks loss PCT Vashington, D.C. 20231 D. G. DAUS Authorized officer D. G. DAUS		and the controls	and the same parent fair	
me and mailing address of the ISA/US Commissioner of Patents and Trademarks Low PCT Vashingron, D.C. 20231 D. G. DAUS D. G. DAUS		can completion of the international search	Date of mailing of the international search	report
me and mailing address of the ISA/US commissioner of Patents and Trademarks tox PCT Vashington, D.C. 20231 D. G. DAUS D. G. DAUS	3 JULY 199	93	31 140	_
ormanisations address of the ISA/US commissioner of Patents and Trademarks lox PCT Vashington, D.C. 20231 D. G. DAUS D. G. DAUS			01 7/46 1993	3 ~
OX PCT Vashingron, D.C. 20231 D. G. DAUS D. G. DAUS	OMMINENODE!	ing address of the ISA/US of Patents and Trademarks		// //
esimile No. NOT APPLICABLE	lox PCT		De Dura / N. Illa -	. Wellers
				1.
Telephone No. (702) 308-1235			Telephone No. (703) 308-1235	-502

INTERNATIONAL SEARCH REPORT

International application No. PCT/US93/04771

Category	mation). DOCUMENTS CONSIDERED TO BE RELEVANT	•
	where appropriate, of the relevant pas	sages Relevant to claim N
A	Jour. MED. CHEM. Vol. 27, 1984, Rasmusson et al "AZASTEROIDS AS INHIBITORS OF RAT PROSTATIC REDUCTASE" pages 1690-1701. See entire document.	
A	Jour. MED. CHEM. Vol. 29, 1986, Rasmusson et al "AZASTEROIDS STRUCTURE ACTIVITY RELATIONSH FOR INHIBITION OF 5 REDUCTASE AND OF ANDROC RECEPTOR BINDING" Pages 2298-2315. See entire documents	77727
A .	E,P, B 0200858 (Cainelli et al.) 12 November 1986. See en doucment.	i.
Y	U.S. A, 4377584 (Rasmusson et al.) 22 March 1983. See Co. 13, No. 19, 21, etc. See entire document.	ol. 1-3, 6-7, 10- 11, 13-17
A	U.S. A, 4760071 (Rasmusson et al) 26 July 1988. See entire document.	1-18
Y	U.S. A, 4882319 (Holt et al) 21 November 1989. See Table	11, 13-17
A	U.S. A, 5049562 (Rasmusson et al.) 17 September 1991. See entire document.	1-18
A	U.S. A, 5116983 (Bahattacharya et al.) 26 May 1992. See en document.	itire 1-18
	U.S. A, 5110939 (Holt) 5 May 1992. See entire doucment.	1-18
	Jour. ORGANIC CHEM. Vol. 54, 1989 Back et al. "NChloro AZASTEROIDS A NOVEL CLASS OF REACTIVE STEROI ANALOGUES. Preparation, Reaction with Thiols and Photo Chenucal Conversion to Electrophilic N Acyl Imines", pages 1904-10. See page 1905 compounds 5 and 6.	D 1, 2, 13
1	U.S. A, 4859681 (Rasmusson et al.) 8 August 1989.	1-18
i I	J.S. A, (Blohm et al.) 2 March 1982. See Col. 2, lines 20 to 4 See entire document.	40. 1-3,6-7, 10- 11,13-17
	TEROIDS Vol. 47, 1986, Brooks et al. "5 Reductase Inhibiton Antiandrogenic Activities of Some 4 Azasteroids in The Raages 1-19. See page 5.	ory 1, 13-17
• •	fethyl-4 Aza-5 Androstau-17B-O, Acetate and Relatel	1-3,6-7, 10-

INTERNATIONAL SEARCH REPORT

International application No. PCT/US93/04771

C (Continu	ALION). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of division of divisi		•
	where appropriate, of the releva	nt passages	Relevant to claim
Y	Jour. Pharm. Sci., Vol. 62, 1973, Doorenbos et al. "Sy and Antimicrobial Properties of 17B Isopreviyloxy-4 Ax Androstane and the 4 Methyl Derivative" pages 638-40. article.	nthesis'	1-3,6-7, 10-11
			•